Fast neutron therapy treatment planning by McGinley, Patton Hopkins
In presenting the dissertation as a partial fulfillment of 
the requirements for an advanced degree from the Georgia 
Institute of Technology, I agree that the Library of the 
Institute shall make it available for inspection and 
circulation in accordance with its regulations governing 
materials of this type. I agree that permission to 'copy 
from, or to publish from, this dissertation may be granted 
by the professor under whose direction it was written, or, 
in his absence, by the Dean of the Graduate Division when 
such copying or publication is solely for scholarly purposes 
and does not involve potential financial gain. It is under-
stood that any copying from, or publication of, this dis-
sertation which involves potential financial gain will not 
be allowed without written permission. 
Z ^ L ^ ^ _ _v_ -
— ' <c3r 
7/25/68 
v 
FAST NEUTRON THERAPY TREATMENT PLANNING 
A THESIS 
Presented to 
The Faculty of the Division of Graduate 
Studies and Research 
by i ( 
v"c" 
Patton HCMMcGinley 
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy 
in the School of Nuclear Engineering 
Georgia Institute of Technology 
August, 1971 
GEORGIA INSTITUTE OF TECHNOLOGY LIBRARY 
Regulations for the Use of Theses 
Unpublished theses submitted for the Master's and Doctor's 
degrees and deposited in the Georgia Institute of Technology 
Library are open for inspection and consultation, but must be 
used with due regard for the rights of the authors. Passages 
may be copied only with permission of the authors, and proper 
credit must be given in subsequent written or published work. 
Extensive copying or publication of the thesis in whole or in 
part requires the consent of the Dean of the Graduate Division 
of the Georgia Institute of Technology. 
This thesis by PATTON HOPKINS MCGINLEY  
has been used by the following persons, whose signatures attest 
their acceptance of the above restrictions. 
A library which borrows this thesis for use by its patrons 
is expected to secure the signature of each user, 
NAME AND ADDRESS OF USER BORROWING LIBRARY DATE 
FAST NEUTRON THERAPY TREATMENT PLANNING 
Approved: ̂  ^ / _j_ 
-// c 
Date approved by/Uhairman: 
xl/(,Jv 
ACKNOWLEDGMENTS 
This report is based upon a thesis submitted to the Georgia 
Institute of Technology in partial fulfillment of the requirements for 
the Doctor of Philosophy Degree. The report describes research carried 
out in the School of Nuclear Engineering at the Georgia Institute of 
Technology. 
The author acknowledges support by the Atomic Energy Commission 
by the award of a Special Fellowship in Radiation Science and Protection 
administered by Oak Ridge Associated Universities. He wishes to express 
gratitude to Professor F. W. Chambers, Jr., thesis advisor, for suggest-
ing the area of study and for help in all aspects of this work. The 
author is also very grateful to the members of his reading committee, 
Dr. G. G. Eichholz, Dr. L. J. Gallaher, and Dr. D. S. Harmer, for their 
encouragement and guidance. 
The author also wishes to express his gratitude for the assistance 
of many of the members of the Health Physics Staff at the Oak Ridge 
National Laboratory and for the use of the DLEA neutron generator. In 
particular, the suggestions and technical assistance of Dr. J. W. Poston 
and Mr. E. M. Robinson have been appreciated. 
Thanks also go to Dr. J. B. Smathers of the Texas A 6c M University 
Department of Nuclear Engineering and to Dr. D. K. Bewley of the Hammer-
smith Hospital Cyclotron Unit for arranging the irradiation of a number of 
LiF dosimeters. 
The author wishes to thank 
support given him while he was in 
should be expressed to the Bennie 
chairman of the "boards," for the 
his wife and children for the moral 
graduate school. A special thanks 
Board Business, of which his wife is 
generous financial aid to his education. 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGMENTS ii 
LIST OF TABLES vi 
LIST OF ILLUSTRATIONS viii 
SUMMARY x 
Chapter 
I. INTRODUCTION 1 
II. GENERAL CONCEPTS 9 
Dose Concept 9 
Deposition of Energy in Matter 
by Fast Neutrons 11 
Requirements for a Dosimetry System 15 
Tissue-Equivalent Material 17 
Radiotherapy Unit 20 
Neutron Source 22 
Neutron Shield and Collimator 27 
Treatment Planning 33 
III. PREVIOUS WORK 39 
Dosimetry Methods 39 
Shielding and Collimation 48 
Depth Dose Data 51 
Summary 55 
IV. INSTRUMENTATION AND EQUIPMENT 56 
Ionization Chambers 56 
Paired Chamber 64 
Thermoluminescent Dosimeters 66 
Neutron Source 71 
Collimator 72 
Phantoms 73 
TABLE OF CONTENTS (Continued) 
Chapter Page 
V. EXPERIMENTAL METHODS 77 
Beam Alignment 77 
Total Dose 77 
Gamma Ray and Neutron Dose 79 
Thermal Neutron Dose 81 
Corrections for Patient Heterogeneity 82 
Percent Dose, Gamma Dose Component, 
and Traverse Function 83 
VI. RESULTS 85 
Collimation and Shielding 85 
Central Axis Depth Dose 88 
Traverse Dose Distribution 93 
Treatment Planning Equation 105 
Corrections for Bone and Lung 107 




A. ERROR ANALYSIS 119 
B. TRAVERSE DOSE FUNCTIONS AND GAMMA 
DOSE COMPONENTS 126 




LIST OF TABLES 
Table Page 
1. 14 MeV Neutron Reactions in Tissue 15 
2. Composition of Muscle and Muscle-Equivalent Materials 
in Percent by Weight 18 
3. Composition of Bone and Bone-Equivalent Material 
in Percent by Weight 19 
4. Isotopic Composition of TLD-100 and TLD-700 45 
5. Reproducibility of Type A Chamber . . . . . 61 
6. Response of Type A and B Chambers to 14 MeV 
Neutrons in Terms of Co Gamma Ray Calibration 64 
7. Dose Measurements with Paired Chambers 66 
8. Values of k for TLD-100 and TLD-700 Obtained 
in This Study 69 
9. Properties of Neutron Beams in Air 87 
10. Central Axis Depth Dose Percentages for 14 MeV 
Neutrons at an SSD of 125 cm 89 
11. Depth Dose Distributions in Cubical and Elliptical 
Phantom for 18.4 x 18.4 cm Field at an SSD of 
125 cm 112 
12. Errors in Voltage Measurements Required for Dose 
Determination 120 
13. Experimental Error in Neutron and Gamma Dose 
Due to Current Variations 124 
14. Traverse Functions and Gamma Dose Components 
for 7.5 x 7.5 cm Field, 14 MeV Neutrons, and 
SSD of 125 cm 127 
V l l 
LIST OF TABLES (Continued) 
Table Page 
15. Traverse Functions and Gamma Dose Components 
for 11.4 X 11.4 cm Field, 14 MeV Neutrons, and 
SSD of 125 cm 128 
16. Traverse Functions and Gamma Dose Components 
for 13 X 13 cm Field, 14 MeV Neutrons, and SSD 
of 125 cm 129 
17. Traverse Functions and Gamma Dose Components 
for 18.4 X 18.4 cm Field, 14 MeV Neutrons, and 
SSD of 125 cm 130 
18. Fitting Constants for Traverse Equation 
(14 MeV Neutrons, SSD = 125 cm) 132 
Vll 
LIST OF ILLUSTRATIONS 
Page 
Geometry for Depth Dose Determination 6 
Tumor Volume, Safety Margin, and Treatment 
Volume (from reference 13) 7 
Plan of a Typical Fast Neutron Therapy Unit 21 
Neutron Spectrum in Air (15 x 15 cm field) 
LRL-ICT(d,t) Source (from reference 19) 24 
Traverse Dose Function at a Constant Depth 29 
Geometrical Penumbra 31 
Build-up Curve for 14 MeV Neutrons (from 
reference 12) 54 
Type A Chamber and Waterproof Holder 58 
Response Curve for Type A Chamber 60 
Directional Response of Type A Chamber 
in Waterproof Container 63 
Comparison of k Values for TLD-100 and TLD-700 70 
Shadow Shield and Collimator 74 
Lung Phantom 76 
Traverse Dose Functions in Air and at the Surface 
of the Phantom for the 13 x 13 cm Field 86 
Central Axis Depth Dose Percentages for 14 MeV 
Neutrons 91 
Central Axis Dose Due to Neutrons 92 
RBE Dose for Neutrons and Gamma Rays (14 MeV 
Neutrons, 125 cm SSD, and 13 x 13 cm Field) 94 
LIST OF ILLUSTRATIONS (Continued) 
Figure Page 
18. Traverse Dose Functions for 11.4 x 11.4 cm Field 
(14 MeV Neutrons, 125 cm SSD) 95 
19. Traverse Dose Functions for Various Field Sizes 
at 10 cm Depth 96 
20. Traverse Dose Functions for Co Gamma Radiation 
and 14 MeV Neutrons 97 
21. Traverse Dose Function for X Ray and 14 MeV Neutrons 
at a Depth of 10 cm 99 
22. Isodose Contours Derived from Experimental Data in 
Table 14 for 7.5 x 7.5 cm Field of 14 MeV Neutrons 
at an SSD of 125 cm 101 
23. Isodose Contours Derived from Experimental Data in 
Table 15 for 11.4 x 11.4 cm Field of 14 MeV Neutrons 
at an SSD of 125 cm 102 
24. Isodose Contours Derived from Experimental Data in 
Table 16 for 13 x 13 cm Field of 14 MeV Neutrons 
at an SSD of 125 cm 103 
25. Isodose Contours Derived from Experimental Data in 
Table 17 for 18.4 x 18.4 cm Field of 14 MeV Neutrons 
at an SSD of 125 cm 104 
26. Traverse Dose Distributions for 18.4 x 18.4 cm Field 
at a Depth of Two Centimeters 109 
27. Central Axis Dose Distrib ution With and Without Bone 110 
28. Neutron Depth Dose in Homogeneous and Heterogeneous 
Phantoms 113 
SUMMARY 
During the last two decades there has been a renewed interest in 
the use of fast neutrons for radiotherapy. At present, a clinical trial 
is being conducted at Hammersmith Hospital, London, using fast neutrons 
with an average energy of 7.65 MeV and future trials, in which 14 MeV 
neutrons will be employed, are being considered. Little information 
exists concerning the dose distribution produced by collimated beams of 
14 MeV neutrons in tissue. Nor have the effects of bone and lung tissues 
on the soft tissue dose distribution been investigated for neutron beams 
of sizes suitable for use in radiotherapy. Information of this type is 
needed for treatment planning of 14 MeV neutron therapy. 
In this research, dose distributions for use in neutron radio-
therapy were experimentally determined. Tissue-equivalent ionization 
chambers were utilized in conjunction with thermoluminescent dosimeters 
to establish the neutron and gamma ray doses deposited in tissue irradi-
ated by beams of 14 MeV neutrons. Dose distributions in homogeneous and 
heterogeneous phantoms containing lung and bone components were deter-
mined at a source-to-skin distance of 125 cm. 
From these measurements it was concluded that the dose distribu-
tions due to 14 MeV neutrons have properties which make them suitable for 
use in radiotherapy. However, improved collimation and shielding systems 
will be required in order to reduce the whole-body dose received by a 
patient undergoing neutron therapy. 
An examination of the dose distributions revealed that the percent 
depth dose at points within the volume of tissue irradiated could be pre-
dicted by means of an empirical equation. Based on these measurements, 
only a slight change in the soft tissue dose distribution was produced 
by bone. On the other hand, an increased dose was found for points in 
and behind the lungs as compared to the dose that would be obtained in a 
homogeneous phantom. 
A discussion of the sources of error in the experimental measure-
ments is included as well as suggestions for future work related to 14 




The aim of the radiotherapist is to destroy tumors while at the 
same time to produce minimum damage to normal tissue surrounding the tu-
mor. In general the radiosensltivity of normal tissue is only slightly 
less than that of malignant tissue. As a result of this fact it may be 
impossible to destroy the tumor without severe damage to normal tissue. 
It is felt by some researchers that the effectiveness of radiotherapy 
could be increased by the use of new types of radiation, such as high 
energy charged particles or neutrons that have an enhanced effect on the 
anoxic portion of tumors as compared to their effect on normal tissue. 
It has been found that the response to conventional radiotherapy 
by X and gamma radiation is significantly influenced by the oxygen con-
centration in the vicinity of cells being irradiated [1,2]. Both cancer-
ous and normal cells show greater sensitivity to radiation at higher 
oxygen concentration. In general the sensitivity to radiation is in-
creased by a factor of three when the survival of well-oxygenated cells 
is compared to that of anoxic cells. 
This oxygen effect may be one of the reasons for failure of X and 
gamma radiation to cure certain cancers. Healthy tissue, due to its 
higher oxygen concentration, tends to be more sensitive to radiation than 
cancerous tissue that contains anoxic regions. Under these conditions 
the dose that can safely be delivered to the treatment volume may be lim-
2 
ited by the radiation tolerance of healthy tissue adjacent to the tumor 
and it may be impossible to deliver a dose of sufficient size to elimi-
nate the tumor. 
This problem of anoxic cells in tumors may be overcome in the fol-
lowing ways : 
1. The sensitivity of all cells in the tumor region may be in-
creased to the same level by increasing the oxygen concentration of the 
anoxic cells. 
2. The sensitivity of cells in and near the tumor may all be re-
duced to the same level by a reduction of the oxygen concentration. 
3. By use of radiation whose effect is independent of oxygen con-
centration both anoxic and oxygenated tissue would be affected to the 
same degree. 
The first possibility has been tested by having the patient breathe 
oxygen at high pressure while receiving radiotherapy. After a decade and 
a half of clinical experiments, there is no substantial evidence that this 
method of radiotherapy is effective. 
The second solution is practical only where the arterial blood 
can be cut off for a short time. Methods have not been found for reduc-
ing the oxygen concentration in tissue without cerebral damage. The 
third possibility of overcoming the oxygen effect by use of new types of 
radiation sources is considered in this thesis. 
It has been found that the magnitude of the oxygen effect depends 
on the linear energy transfer (LET) of the radiation employed, with high 
LET radiation being relatively independent of oxygen concentration in its 
effect on normal and tumor tissue [2,3,4_|. 
The term "linear energy transfer" was introduced by Zirkle et al. 
[5] to describe the spatial distribution of energy dissipated in matter 
by ionizing radiation. The LET is usually expressed in terms of keV per 
micron path length of absorber. 
Gamma and X ray photons with energy of more than 100 keV produce 
low LET (0.2 to 3 keV/u,) secondary electrons in tissue. On the other 
hand, alpha particles produced by the decay of naturally occurring radio-
active materials have high LET values of the order of about 100 keV/^ in 
tissue. The LET of ionizing particles is a function of their mass and 
velocity with high LET being produced by low speed and high mass particles. 
Charged particles of LET greater than a few keV/jj, have a short 
range in tissue. Therefore, the effect of high-LET particles on animals 
or animal tissue has been studied mainly by the use of fast neutrons 
which have no charge and can penetrate deeply into tissue. High-LET par-
ticles, such as recoil protons and alpha particles, are produced by the 
interaction of neutrons with tissue. Biological changes are produced by 
the energy deposited in tissue by these particles. Chapter II of this 
thesis covers the details of neutron interactions with matter and the 
types of particles produced. 
If high-LET radiation is employed for tumor treatment, the anoxic 
parts of the tumor mass will be affected almost to the same extent as nor-
mal oxygenated tissue. Therefore, radiotherapy utilizing fast neutrons 
or high energy charged particles may be more effective than conventional 
tumor therapy with low LET X ray and gamma rays. 
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A neutron source suitable for external beam therapy, in which the 
radiation source is located outside of the patient's body and a colli-
mated beam of radiation is used to irradiate the tumor, should exhibit 
the following characteristics: 
1. small oxygen effect for the neutrons emitted; 
2. high penetration in tissue for the neutrons emitted; 
3. reasonable size and cost; 
4."*" low weight, so that positional and angular control of the beam 
are possible; 
5. high source strength, so that a high dose rate is produced at 
the location of the patient to minimize treatment time. 
The first factor, the oxygen effect, has been determined for neu-
2 3 9 trons produced by the following reactions: fission, H(d,n) He, Be-
(d,n) B, and H(d,n) He [6,7,8,9]. The neutrons produced by these reac-
tions exhibit only minor oxygen effect and may therefore be suitable for 
radiotherapy. 
It has been found that neutrons from the first and second reactions 
[9,10] do not have sufficient penetration for external beam therapy. Neu-
trons produced by bombarding a beryllium target with deuterons have pene-
tration that is barely acceptable for therapy C11J - Neutrons produced by 
the H(d,n) He reaction meet the first four requirements [7,9,12], but 
the available source strength is too low for radiotherapy. It is felt 
that it is technically feasible to remedy this defect by improved target 
design using some of the methods reviewed in Chapter II. It is for these 
reasons that clinical trials are being considered at the University of 
5 
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Pennsylvania Hospital utilizing neutrons produced by the H(d,n) He reac-
tion [13]. 
Before clinical trials are initiated,dose distributions in tissue 
must be obtained for use in treatment planning. Dose distributions for 
use in treatment planning are commonly expressed in terms of the percent 
depth dose (P ) which is defined as 
x , y 
Px,y = f ^ 1 M ' W 
o 
where 
D = dose a t a re fe rence po in t along the c e n t r a l ax i s ( u s u a l l y 0.5 
fin 
cm depth below the skin su r face for Co) 
D = dose a t point ( x , y ) . 
x ,y 
A t y p i c a l geomet r i ca l arrangement of the r a d i a t i o n source and the p a t i e n t 
is shown in F igure 1. The source is loca ted a t po in t S and the edge of 
the beam is shown as s o l i d l ines from S to L and L ' . The sur face of the 
p a t i e n t is loca ted along l ine LL' . Length i i s used in some of the t r e a t -
ment planning equa t ions tha t fo l low. This length is the d i s t a n c e between 
point 0 and the p o i n t where the l i n e from source S to po in t (x ,y ) i n t e r -
sec t s the skin of the p a t i e n t . Tne d i s t a n c e from the source to the skin 
of the p a t i e n t i s given by length SO and i s c a l l e d the s o u r c e - t o - s k i n 
d i s t a n c e (SSD). The l i n ? through the c e n t e r of the beam along SO is 
ca l l ed the c e n t r a l a x i s . Percent depth dose values for po in t s along t h i s 
axis w i l l be i n d i c a t e d by the symbol P 
o,y 
The main purpose of t reatment planning is to a s su re adequate tumor 
Central Axis 
Surface of Patient 
Figure 1. Geometry for Depth Dose Determination 
7 
dose and minimum dose to healthy tissue. This goal is attained by use of 
multifield techniques, rotational methods and control of field size and 
treatment distance. An outline of these methods is given in Chapter II 
and a brief summary of a typical treatment plan is given below. 
In tumor treatment it is inevitable to expose some healthy tissue 
to almost the same dose as that delivered to the tumor. Figure 2 shows 
several regions associated with a tumor mass. In computing the exposed 
tissue volume the actual tumor and a surrounding region referred to as 
the "safety margin" are assumed to constitute the mass to be exposed. The 
safety margin is added to the outermost boundaries of the tumor to allow 
for uncertainties in tumor size and to possibly include sub-clinical ex-






Figure 2. Tumor Volume, Safety Margin, and Treatment Volume 





Irradiation of the tumor mass is achieved by exposure to several 
converging radiation fields in the same horizontal plane. This procedure 
considerably reduces the skin dose and the dose to overlying normal tissue. 
By employing this multifield method a roughly cylindrical volume, somewhat 
larger than the safety margin volume, receives a high absorbed dose. 
The "treatment volume" usually contains part or all of some essen-
tial organ whose sensitivity to radiation limits the dose deliverable to 
the nearby tumor mass. Irreparable damage may be done to surrounding nor-
mal tissue at dose levels less than that required to "kill" the tumor. 
Therefore, an evaluation of each treatment procedure must be made based 
on the dose distribution in the volume of irradiated tissue. 
The objective of this investigation is to obtain tissue-dose dis-
tributions for collimated beams of 14 MeV neutrons and to develop treat-
ment planning equations for fast neutron therapy. The investigation can 
be divided into four related parts. They are 
1. design and construction of a fast neutron collimator and 
shield, 
2. measurement of physical properties of the fast neutron beam 
produced by the collimator in air and tissue-equivalent material, 
3. determination of percent dose distributions due to 14 MeV neu-
trons in tissue equivalent material, and 
4. analysis of the depth dose data to obtain relationships be-
tween the percent depth dose and parameters such as depth in tissue, dis-




The purpose of this chapter is to summarize the problems and 
requirements associated with the prediction of dose distributions for 
use in 14 MeV neutron treatment planning. Also considered are the con-
cepts necessary for an understanding of these problems. 
Dose Concept 
Specifying biological effects produced by a given radiation 
exposure in terms of a single parameter is difficult. It has been the 
general approach to assume that the effect of radiation can be corre-
lated with the energy absorbed. The basic concept of "absorbed dose" 
was defined by the International Commission on Radiological Units [14] 
AEd 
D = ^ r • <2> 
where 
D = absorbed dose 
AE = energy imparted by ionizing radiation to matter in a volume 
of mass Am. 
The unit of absorbed dose is the rad which is equivalent to 100 
ergs of energy absorbed per gram of matter. It should be noted that this 
definition of radiation dose is more general than some of the older units 
such as the roentgen in that neither the absorbing material or the type 
of radiation is specified. 
The degree of ionization produced in air by X or gamma radiation 
is used to determine the exposure (X) as shown by equation 3. 
i = S- « 
The term AQ represents the sum of the electrical charges on all ions of 
one sign produced in air when all secondary electrons liberated by pho-
tons in a volume of air of mass Am are completely stopped in air. The 
roentgen (R) which represents the liberation of 2.58 x 10~4 Coulombs of 
charge of one sign per kg of air is used as the unit of exposure. 
The magnitude of damage produced by the exposure of a biological 
system to equal absorbed doses of different radiations may be quite dif-
ferent. In the medical field the "RBE dose" is used to indicate the de-
gree of biological damage produced by an absorbed dose (D) of a given type 
of radiation. The RBE dose for a particular type of radiation (type A) 
is defined as 
RBE dose = (D)(RBE) , (4) 
where 
D = absorbed dose(rad) 
RBE = relative biological effectiveness of radiation (type A) com-
pared with the effect of X or y radiation. 
For a given type of radiation the RBE factor can be defined as 
11 
/Dose of 250 keV X rays \ //Dose of radiation- "N 
RBE = ;j or gamma rays producing /|A producing the same I (5) 
ya given biological effect// \biological effect / 
The RBE dose is a relatively awkward concept in the sense that 
many different factors influence RBE values. For example, the RBE of a 
radiation may depend on the type of biological effect considered, temper-
ature, the dose, the dose rate, LET, oxygen concentration, etc. It has 
been estimated that the conditions encountered in fast neutron therapy 
may result in a RBE of 2.5 to 3.0 [4,13,15]. 
Deposition of Energy in Matter by Fast Neutrons 
In order to develop instruments and techniques for use in the de-
termination of the absorbed dose in patients undergoing neutron therapy, 
knowledge of the mechanism of energy deposition in matter by fast neutrons 
is desirable. The following section is a survey of the basic interaction 
of neutrons with matter with special emphasis on neutron interactions in 
tissue. 
When matter is irradiated with neutrons the primary interaction 
is at the nuclear level since neutrons are uncharged and there will be 
only slight interaction with orbital electrons. In general the inter-
actions are of two types, scatter and absorption of neutrons by the tar-
get nuclei. Neutron scattering reactions may be of the elastic or ine-
lastic type. Elastic scattering events are those in which the neutron 
collides with the nucleus of an atom and some of the kinetic energy of 
the neutron is transferred to kinetic energy of the struck nucleus. The 
struck nucleus is not left in an excited state and kinetic energy is con-
12 
served in the collision. The energy of the neutron (E1) after collision 
is given by 
E' = E A3 + 2A V l , (6) 
(A + l)3 
where 
E = initial energy of the neutron 
A = atomic weight of scattering material 
uo = cosine of the scattering angle in the center-of-mass coordi-
nate system. 
Maximum loss of kinetic energy of the neutron occurs for scatter-
ing materials with low atomic weight and for large angles of scatter. 
The probability for elastic scattering tends to increase as the neutron's 
energy becomes small. The neutron may also undergo scatter and leave the 
nucleus in an excited state. Scattering of this type is called inelastic 
scattering and it occurs with increasing probability as the energy of the 
neutron becomes large. Above 3.0 MeV neutron energy, about half of the 
total cross section for materials with medium and high atomic weight is 
due to inelastic scattering [16]. On the average the energy of the neu-
tron is reduced to below 2.0 MeV as the result of any single inelastic 
scattering event in matter [16]. 
Neutron absorption by the target nucleus may result in such reac-
tions as the following types (n, a) , (n,2n), and (n,p). These reactions 
are prevalent for neutrons with energy of several MeV and their cross 
sections increase with energy. Exceptions to this general rule are the 
13 
B(n,oO Li and the Li(n,a) H reactions which have large cross sections 
at low neutron energy. The (n,2n) reaction becomes energetically possible 
when the energy of the incident neutron is larger than the binding energy 
of the last neutron in the target nucleus. Depending on the nucleus in 
question, the binding energy of the last neutron varies from 1.67 to 20.4 
MeV. 
An absorption reaction in which the neutron enters the nucleus and 
no particle is emitted is usually called neutron capture. This reaction 
occurs with high probability at low neutron energy and a compound nucleus 
is formed in an excited state due to the binding energy released as a re-
sult of neutron absorption. The compound nucleus usually releases this 
excess energy by the emission of one or more capture gamma rays and the 
product nucleus undergoes radioactive decay. 
In tissue neutron interactions are primarily with nuclei of hydro-
gen, carbon, oxygen, and nitrogen. Less important reactions occur with 
calcium and phosphorus. Heavy charged particles (protons, deuterons, 
alpha particles, and recoil C, N, and 0 nuclei) with high LET are released 
in tissue by fast neutrons through recoil effects and absorption reaction. 
In summary, the five main reactions by which fast neutrons deposit 
energy in tissue are listed below. 
1. Elastic scattering of neutrons by hydrogen is the most impor-
tant interaction in terms of energy deposited per gram of tissue. Recoil 
protons contribute 94 percent of the absorbed dose at 0.3 MeV and this 
percentage drops to 70 percent at 14 MeV neutron energy due to the decreas-
ing cross section for this interaction. 
2. Neutron absorption by oxygen is the second most important fast 
16 13 
neutron interaction in tissue. In particular, the reaction 0(n,CX) C 
will result in high LET a particles being produced in tissue. About 11 
percent of the absorbed dose due to 14 MeV neutrons is produced by this 
reaction in tissue [l7]. 
3. Recoil nuclei other than hydrogen recoils are produced in tis-
sue due to fast neutron interactions. These recoil nuclei have short 
track length and very high LET. About 10 percent of the absorbed dose 
due to 14 MeV neutrons is due to this process. 
4. Radiative capture of slow neutrons by hydrogen in tissue leads 
to the production of 2.21 MeV gamma rays. This reaction has low proba-
bility at high neutron energies, but becomes important after the neutron 
has been slowed by a series of collisions with nuclei in tissue. 
5. Neutron absorption by nitrogen also has high probability at 
low neutron energy and results in the production of 0.6 MeV protons by 
14 14 
the N(n,p) C reaction. Less than 0.2 percent of the absorbed dose due 
to 14 MeV neutrons is produced by this reaction. 
In addition to the interactions mentioned above, energy may be 
lost by neutrons in tissue by inelastic scattering. About four percent 
of the energy deposited in tissue by 14 MeV neutrons is due to recoil 
nuclei produced by inelastic scattering. Randolph [17] has indicated 
that there are at least 17 nuclear reactions and 25 products contributing 
to the absorbed dose in tissue due to 14 MeV neutrons. The principal 
reactions and the fraction of the absorbed dose due to the reaction prod-
15 
ucts are outlined in Table 1. 
Table 1. 14 MeV Neutron Reactions in Tissue [17] 
Reaction Ionizing Fraction of Average LET FL 
Product Total Dose (F) L (keV/^) e 
HCn,n)H P 
0 (n , a) C Oi 








11 others 19 others 
0.704 25 17.6 
0.106 90 9.5 
0.046 750 34.2 
0.030 500 15.2 
0.035 670 23.6 
0.009 700 6.3 
0.017 130 2.2 
0.056 291 16.3 
Overall energy average LET -- 124.9 keV/|i 
Energy average LET from H -- 25 
Energy average LET from all other elements -- 362 
About 70 percent of the dose is delivered at an energy average LET 
of 25 keV/(i due to elastic scatter by hydrogen. The remaining 30 percent 
of the absorbed dose, due to elastic scatter and nuclear reactions with 
0, C, and N, is at a higher LET value. 
Requirements for a Dosimetry System 
Neutron beams almost always have associated with them a gamma ray 
16 
component. These gamma rays are produced by capture reactions and ine-
lastic scattering of neutrons in the shield and collimator material and 
in tissue. X rays are inavoidably produced in neutron generators and Y-
ray dose levels near the target have been reported at 25 to 450 mR/hr [18] 
In the case of well-collimated 14 MeV neutron beams the gamma dose com-
ponent can be relatively small and little build-up of this component has 
been noted in tissue-equivalent materials [l9]. For therapy purposes it 
is desirable to determine the absorbed dose due to neutrons.and gamma rays 
separately. Each component can then be weighted by a clinical RBE factor 
to obtain the biological damage produced by the radiation. 
In order to obtain depth dose values for use in neutron therapy 
planning a dosimetry system should be employed that has the following 
characteristics . 
1. Capability of resolving the absorbed dose in tissue into gamma 
and neutron components. 
2. Small size in order to produce minimum perturbation of the 
radiation field. 
3. Capability of dose rate determination at 125 cm from the tar-
get of a conventional neutron generator (20 to 200 mR/min), 
4. A high degree of stability is required since depth dose studies 
typically require several months time. 
5. For the reasons given in the next section of this chapter, 
depth dose distributions are usually determined by measurements made in 
tissue-equivalent liquids. Therefore, the dosimeters should be rugged 
and waterproof since they will be used in a liquid phantom. 
Tissue-Equivalent Materials 
For reasons of convenience and cost, dose distribution studies are 
almost invariably carried out by measuring the dose at selected points 
within a suitably shaped solid or liquid-filled model known as a phantom. 
For valid comparisons such a phantom must be made of material that closely 
reproduces the composition and spatial distribution of body tissues. 
In order for a material to be tissue-equivalent (TE) for neutrons, 
it must have the same elemental composition as tissue. True tissue-
equivalent solid materials have not been developed due to difficulties in 
reproducing the required oxygen content. However, TE solutions can 
easily be prepared for use as a phantom to simulate the patient's body. 
Tables 2 and Table 3 list the composition of muscle and bone and some of 
the tissue-equivalent materials available at present. Since most of the 
energy deposited in tissue by fast neutrons is due to interactions with 
hydrogen, the hydrogen content of any tissue substitute material should 
be closely matched to that of tissue. It should be noted that the oxygen 
and carbon content of TE plastic (A-150) are almost reversed as compared 
to soft tissue or muscle. Corrections for this reversal of oxygen and 
carbon content in this material are discussed in Chapter III. 
In order to obtain realistic dose distributions, one should use a 
heterogeneous phantom that contains muscle, lung, and bone components. 
The shape and dimensions of the phantom should be similar to those of an 
average patient. Lung-equivalent material should have a composition 
similar to that of muscle [20 J but with a density in the range of 0.2 to 
0.5 gm/cm3 [2l]. A lung phantom could be constructed of muscle equivalent 
plastic interspersed with small air spaces. 
Table 2. Composition of Muscle and Muscle-Equivalent 
Materials in Percent by Weight 
Element Typical TE Gas TE Gel 
Muscle I 
[22] [23] [23] 
H 10.2 9.7 10.0 
C 12.3 15.7 14.9 
N 3.5 3.5 3.5 
0 72.9 71.1 71.6 
other . 
elements 
TE Plastic TE Gas TE Liquid 
A-150 II 
[24] [23] [25] 
9.9 10.1 10.2 
77.1 45.7 12.0 
4.4 3.5 3.6 
5.0 40.7 74.2 
3.6 
Explosive mixture 
Table 3. Composition of Bone and Bone-Equivalent 
Material in Percent by Weight 
Element Bone Bone-Equivalent 
Plastic B-100 
[22j [26] 
H 6.4 6.39 
C 27.8 53.41 
N 2.7 2.67 
0 41.0 3.06 
Ca 14.7 17.69 
P 7.0 






If 14 MeV neutrons are to be used for therapy, adequate shielding 
and collimation must be provided to minimize the exposure of healthy 
tissue to radiation. In general terms, a typical radiotherapy unit for 
fast neutron treatment may take the form shown in Figure 3. The walls, 
ceiling, and floor of the treatment room serve as a primary radiation 
barrier and are constructed of concrete. The primary barrier is used to 
reduce the radiation levels outside the treatment room in order to pro-
tect the hospital's patients and staff. It has been reported [27,28] 
that the thickness of the primary barrier must be of the order of seven 
feet of concrete. The neutron source itself is surrounded by a shield and 
collimator system in order to provide a beam of neutrons and to reduce 
the whole body dose to the patient. Minimum dose to tissue outside the 
target volume is essential due to the deleterious effects produced by 
neutrons on the blood forming organs, lenses of the eyes, and skin of the 
patient. The patient is shown in Figure 3 in the supine position on the 
treatment couch. Alignment of the patient and the beam is usually ob-
tained by use of a light source that projects a beam of light through the 
collimator. The light beam is aligned with markings on the skin of the 
patient corresponding to the desired entrance port for the beam. The 
neutron source could also be used to make a diagnostic radiograph from 
which the alignment of the tumor and the beam could be determined. 
The basic components of the therapy unit are the neutron source, 













Figure 3. Plan of a Typical Fast Neutron Therapy Unit 
Neutron Source 
Fast neutrons of energy of approximately 14.6 MeV are produced by 
3 4 
the H(d,n) He reaction. Neutrons generated by this method are usually 
referred to as DT or 14 MeV neutrons. In employing this reaction, a beam 
of deuterons is directed against a tritium-containing metal disc. The 
fast neutron flux emerges almost isotropically from the tritium target 
and only slight variation of the neutron energy with the angle of emission 
from the target has been observed. For example, at an incident deuteron 
energy of 150 keV, neutrons with energy of 14.7 MeV are emitted in the for-
o 
ward direction and with 13.4 MeV energy at an angle of 180 with respect 
to the incident deuteron beam [29]. 
A typical commercial neutron generator utilizes a Cockcroft-Walton 
voltage generator to produce accelerating potentials of the order of 150 
to 200 keV. Higher potentials result in increased cost and complexity 
due to insulation problems. The tritium target consists of a copper disk 
onto which a thin layer (2 to 2.5 mg/cm2) of titanium has been evaporated. 
Several curies of tritium are incorporated into the titanium layer by 
absorption. A deuterium ion current of about 2.0 mA is used to achieve 
neutron yields of the order of 1 x 1011 neutrons/sec. 
Due to the loss of tritium from the target as a result of deuteron 
bombardment, which heats the target and causes "boiling off" of the tritium 
into the beam tube vacuum system, the target half life (i.e., the time re-
quired for the neutron yield to decrease to half of the initial value) is 
relatively short, being of the order of an hour or less when a high beam 
current is used. 
A neutron spectrum obtained at a distance of 125 cm from a tritium 
target is shown in Figure 4 [l9]. The target was bombarded with 400 keV 
deuterons and threshold detectors were used to obtain the neutron energy 
spectrum. To minimize the presence of scattered neutrons the source was 
located on a light-weight metal floor in the middle of a cubical room 
measuring 40 feet on each edge. 
For neutron radiotherapy it is necessary that the neutron source 
produce a high dose rate at the location of the patient and have rela-
tively long life. Brennan [9] has suggested that the minimum dose rate 
acceptable for neutron therapy is 10 rads per minute at the surface of 
the patient. This dose rate corresponds to a neutron flux of approximately 
2 x 107 neutrons per cm per second. This value for the minimum dose rate 
was based on the following considerations. Accurate alignment of the beam 
and tumor volume can be maintained only for a relatively short time due to 
movement of the patient. At best, the patient can be expected to remain 
immobile for a period of about 15 minutes. 
Also, if a statistically significant number of cases is to be 
treated (> 24 patients per day) for a clinical trial, a dose rate of this 
magnitude is required. To obtain a dose rate of 10 rads per minute, a 
neutron source yield of 4.0 X 1012 neutrons per second is required if the 
patient is to be treated at a distance of 125 cm from the target. Smaller 
treatment distances will probably not be used since unfavorable dose dis-
tributions result [9]. 
A target life time of at least 30 hours [13] is desirable for 
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Figure 4. Neutron Spectrum in Air (15 X 15 cm field) LRL-ICT(d,t) 
Source (from reference 19) 
approaches are being investigated at present to increase the neutron 
yield and target life time. The neutron output could be increased by use 
of large area targets and increased beam current. A neutron generator 
has been constructed by the Health Physics Group of the Oak Ridge National 
Laboratory in which a 35 cm diameter target containing 1500 to 2000 Ci of 
tritium was bombarded by a beam current of 500 mA [30,3l]. A target life 
of four hours was obtained for continuous operation at a source yield 
greater than 1 X 1013 neutrons per second. However, it is felt that col-
limation problems would result if targets larger than 2.54 cm diameter 
are used for neutron therapy [32]; also, the use of 1500-2000 Ci of H 
in a single target poses serious safety and contamination problems. 
Therefore, other approaches for increasing the neutron yield and target 
life are being explored. 
A mixed beam approach is being considered by the British Services 
Electronic Research Laboratory [33]. The target contains both deuterium 
and tritium and both tritium and deuterium ions are accelerated into the 
3 4 2 4 
target. The following reactions occur: H(d,n) He, H(t,n) He, and 
2 3 
H(d,n) He, but the yield of the last reaction is relatively low. By use 
of tritium and deuterium in both the target and the beam, target life 
times of 80 to 100 hours have been obtained at a yield of 1 x 1011 neu-
trons per second [34]. The mixed beam method has been used with sealed 
tubes to eliminate the need for a vacuum pumping system and gas transfer 
equipment. By use of a sealed source, the tritium health hazard is re-
duced since large amounts of tritium gas do not have to be pumped through 
a vacuum system. 
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The Aero-Jet Corporation [35] has developed high yield ion sources 
for the production of 650 mA beams of deuterium or tritium ions. These 
ions can be focused into a beam having a diameter of two centimeters or 
less. At present this group is investigating the development of a radio-
therapy target in which both deuterium and tritium ions are used to bom-
bard a bare copper plate. Loss of tritium by the "sputtering off" of the 
Ti layer is avoided by this system. 
The possibility of employing a gas target containing gaseous tri-
tium is being investigated [36]. Preliminary studies indicate it may be 
possible to obtain a source yield greater than 1 X 1013 neutrons per sec-
ond by use of gas targets. 
One of the larger 14 MeV neutron generators in this country is 
located at the Lawrence Radiation Laboratory, California [l9]. This 
neutron generator utilizes a target which consists of a disc of copper 
with a layer of tritium on the surface. The target is rotated at 1100 rpm 
and a two centimeter beam of deuterium ions strikes the edge of the disc. 
An emission rate of 1 x 1012 neutrons per second and a target life of 30 
to 40 hours has been reported for this generator [l2]. 
If 14 MeV neutrons are to be used for therapy, the source output 
must be increased and longer target life must be obtained. From the 
studies reviewed above, it appears to be technically feasible to achieve 
a neutron yield of 4 X 1012 neutrons per second and a target half life 
greater than 30 hours. At the moment the neutron yield obtainable from 
commercial generators is adequate for depth dose studies. 
Neutron Shield and Collimator 
To avoid exposing a major portion of the patient's body to large 
neutron doses, a shielding system is required for fast neutron therapy. 
A neutron shield suitable for external beam therapy should meet the fol-
lowing basic requirements. 
1. The shield should produce an attenuation of the dose by a 
factor of at least 98 percent for points near the edge of the beam. 
2. The whole body dose should be one percent or less of the tumor 
dose. 
3. The shield weight should be minimal for easy positional and 
angular control of the neutron beam. 
4. The maximum shield length should be less than 125 cm. 
The first requirement is based on the fact that the dose due to 
radiation backscattered from the patient at points a few centimeters out-
side of the beam is about 2.0 percent of the dose at the center of the 
neutron beam [27]. Therefore, there is no need for the shield to produce 
an attenuation of the dose by a factor much greater than 98 percent for 
points near the beam edge. The second requirement is based on the fact 
that a tumor dose of several hundred rads will be required for neutron 
radiotherapy. If the patient's whole body is exposed to dose levels much 
greater than 1.0 percent of the tumor dose, unacceptable somatic injury 
may result. 
In order to position the beam accurately with respect to the 
patient, a shield of relatively low weight is required. A source plus 
shield weight of as much as seven tons could be used with standard Co 
28 
therapy mountings [34], The requirement for maximum shield length of 125 
cm is based on the following considerations. To obtain favorable dose 
distributions in tissue, the patient must be treated at a distance of at 
least 125 cm from the source [9]. On the other hand, to obtain an accep-
table dose rate (10 rad/min) the patient may have to be treated as close 
to the source as possible. Thus, a treatment distance of 125 cm will 
probably be used for neutron therapy. 
The terms field size, field flatness, and beam sharpness will be 
used in this thesis to describe radiation beam characteristics. A typi-
cal beam profile is shown in Figure 5. A distribution of this type will 
be called a traverse dose function. The value of this function at a 




F = ^ , (7) 
where 
F = traverse dose function 
D = dose at a point x distance from the central axis and a 
x,y 
depth y 
D = dose at a point on the central axis and a depth y. 
o,y 
The field size is obtained from the traverse dose function at the 
surface of the patient. This quantity is determined at the point where 
the function F has a value of 0.5. In some of the equations that follow, 
the field size is represented by the symbol 2L. Beam size is used as a 





















x (distance from central axis) 
Figure 5. Traverse Dose Function at a Constant Depth 
The beam size is determined at the point where the traverse dose function 
has a value of 0.5 for the depth in question. 
The beam flatness (f) at depth y is defined as 
f = ^ X 100 , (8) 
y 
where 
x1 = traverse distance from central axis to the point where F has 
a value of 0.90 
L = half-width of the beam at depth y. 
The beam sharpness as used in this thesis is defined as the dis-
tance required for F to decrease from 0.80 to 0.20. This distance is 
measured traverse to the central axis and is shown in Figure 5 by the 
symbol s. These values of F were selected to describe the dose distri-
bution at the edge of the beam due to the fact that, in this range, F de-
creases in nearly a linear fashion with distance x. A second term simi-
lar to the beam sharpness may be used to describe the dose distribution 
at the edge of the beam. The origin of the geometrical penumbra [37] is 
illustrated in Figure 6 and it can be calculated by use of equation 9. 
/d-SDD\ / source \ /n, 
P = fey) X (diameter) • ( 9 ) 
where 
SDD = distance from source to distal end of collimator 
d = distance from source to point where p is obtained. 
Typical values of p for Co radiotherapy units range from ap-
proximately zero to five centimeters at the surface of the patient. For 
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Figure 6. Geometrical Penumbra 
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radiotherapy purposes the beam sharpness is a more suitable description 
of the beam since it is based on dose measurements made in tissue or 
tissue-equivalent material. 
In order to obtain a uniform dose in the treatment volume and 
low dose outside of this region, a radiation beam should have a large 
beam flatness and low beam sharpness. In addition, the dose level in the 
area outside of the beam should be low. Typical values of these quanti-
ties for a 10 X 10 cm Co beam at a depth of one centimeter are 0.5 cm 
beam sharpness, 85 percent beam flatness, and an F value of 0.01 to 0.02 
outside the beam. On the other hand, typical X ray beams have larger 
beam sharpness and lower beam flatness. For example, values of eight 
centimeter beam sharpness and 42 percent beam flatness are found for an 
X ray beam (250 kV, 2.5 mm half value thickness, 10 X 10 cm field size) 
at a depth of 10 cm in the tissue. 
A collimator for use in neutron therapy or a depth dose study 
should produce a beam that is well defined and that has relatively low 
contamination by slow neutrons and gamma rays. The desired properties of 
a fast neutron beam for clinical use are listed below. 
1. The beam flatness and sharpness in tissue should be comparable 
to that obtained for X ray beams used in therapy [32]. 
2. A beam with 5 to 10 percent gamma dose contamination would be 
acceptable for radiotherapy [l3]. Since gamma rays are used for treat-
ment of cancer and tumors, a 50 percent gamma dose contamination could be 
tolerated . 
3. The beam should have a minimum slow neutron dose component of 
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a few percent of the total dose [32] to minimize the skin and near surface 
dose and activation of equipment. 
4. The penetration of the neutron beam in tissue should be such 
that the dose at a depth of 10 cm is at least 50 percent of the dose 
near the surface [13]. 
Beam definition similar to that of therapeutic X ray beams is sug-
gested since radiotherapy can be carried out successfully with X ray beams. 
The requirement for a minimum reduction in dose of 50 percent in 10 cm of 
tissue is based on treatment planning considerations which are explained 
in the next section. 
Treatment Planning 
Treatment planning for radiotherapy aims to optimize treatment 
procedures so that a maximum dose is delivered to the tumor with a mini-
mum dose deposited in healthy tissue. In general, it is desirable to use 
an electronic computer for treatment planning since many alternative 
treatment conditions must be considered. A brief review of the general 
approach of calculation of dose distribution within the patient is given 
below. 
Radiotherapy planning can be divided into three distinct steps. 
The first of which is the determination of the percent dose at any point 
within a given block of soft tissue irradiated by a single stationary beam 
of radiation. In the second step of treatment planning, corrections are 
made of the dose distribution obtained in step one to account for patient 
contour and heterogeneity and for beam modifying filters and penumbra ef-
fects. As a last step, depth dose distributions are produced for multi-
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field and rotational therapy by systematic summing and interpolation of 
the distributions for single fields. The radiologist can now determine 
the suitability of a particular treatment plan by examination of the dose 
distribution produced in step three. Factors such as the uniformity of 
the dose distribution in the tumor volume, the amount of healthy tissue 
irradiated, the extent of the safety margin, and the maximum dose to 
healthy tissue are used to evaluate a treatment plan. 
Multifield and rotational therapy are used to treat tumors that 
lie at considerable depth below the skin. It has been found that treat-
ment of deep tumors with a single field usually results in excessive 
damage to healthy tissue. This damage can be avoided by use of the multi-
field technique in which two or more beams of radiation with different 
portals of entry are aimed at the tumor volume. Rotational therapy in 
which the source is revolved about the patient with the beam aimed con-
tinually at the tumor is an outgrowth of the multifield technique. For 
treatment of tumors of the trunk region of the body by the rotational or 
multifield method, the radiation should have a degree of penetration that 
will result in the 50 percent depth dose occurring at a depth of at least 
10 cm. With this degree of penetration, dose distributions can be ob-
tained for multifield and rotational therapy that have higher tumor dose 
than the dose to healthy tissue outside the treatment region. 
It should be pointed out that the basic problem in computer therapy 
planning is the generation of a single-field dose distribution. At pres-
ent, the majority of the methods used to calculate single-field distribu-
tions are of the form shown by equation 10. 
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P = P X F , (10) 
x,y o,y 
where 
P = percent depth dose at point (x,y) x >y 
P = percent depth dose at depth y alone central axis 
o,y r r t- J o 
x = distance off central axis 
y = depth in patient 
F = traverse dose function. 
Equations fitted directly to percent depth dose values have been 
used to generate values for P . One of the newer and more successful 
o,y 
empirical equations was developed by Sterling [38]. This relationship 
was based on the fact that the percent depth dose was shown to be a 
simple function of the logarithm of the ratio of the area to perimeter 
of the field, the depth below the surface, and the source-to-skin dis-
tance. For a fixed SSD the expression takes the form 
log P = m log(A/E) + h , (11) 
where 
P = percent depth dose at depth y along the central axis 
A = area of field 
E = perimeter of field 
h and m = fitting constants. 
f->n 
It was found that, for Co gamma radiation, h and m are linear 
functions of depth below the surface according to equations 12 and 13 
h = ay + b , (12) 
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m = a'y + b' , (13) 
where a, b, a', and b' are experimentally determined constants. 
Combining equations 11, 12, and 13 gives equation 14. 
P = antilog [ay + (a'y + bf) log(A/E) + b] . (14) 
Four fitting constants are needed in equation 14 to describe the 
central axis dose distribution for all field sizes of clinical interest 
at a fixed SSD. Agreement between observed and calculated percent dose 
values was found by Sterling [38] to be within 2.0 percent for depths 
from 1 to 20 cm in tissue. 
The function P may also be determined by use of tissue-air 
o,y 
ratios (TAR) [39,40]. This ratio relates the dose in air to the percent 
depth dose in tissue at the same point on the central axis. 
To obtain percent dose values at points off the central axis, 
values of the function F are required. According to Clifton and Galla-
gher [4l] the various methods used to represent the traverse dose function 
fall into three groups: 
1. Specific Cross Plot Data. 
2. Representation of Primary and Scatter Contributions. 
3. General Empirical Curve Fit. 
The first group requires large amounts of computer memory, and 
interpolation techniques are needed to generate dose values for points 
not included in the list of data. The decrement line system developed by 
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Ochard [42] offers an efficient method of obtaining dose values from a 
minimum number of experimental measurements. 
The second group of algorithms has evolved from methods suggested 
by Clarkson [43] and Meredith and Neary [44] in which the percent dose at 
a point is obtained by separate calculation of the primary and scattered 
radiation components. Much use of this system has been made in conjunc-
tion with the TAR method for computer-generated depth dose distributions. 
Sterling [38] has used empirical curve fitting methods to obtain 
a simple traverse dose function. It was found that the traverse dose 
function could be represented by the cumulative probability function shown 
by equation 15. 
F = 1 - J"7' -^- e*p {- [<VL) -jl>\ dU/L) (15) 
J.oo \T5no ^ 2a2 J 
where 
F = traverse dose function 
I = distance from central axis to the point where the line from 
source S to point (x,y) intersects the skin of the patient 
(see Figure 1) 
L = half field width 
\x,a = experimentally determined constants. 
Computer programs have been written which are based on the al-
gorithms developed by Sterling for the central axis and traverse dose 
function [45]. Programs of this type can be used to determine three-
dimensional dose distributions in which many of the corrections required 
for treatment planning have been taken into consideration. 
38 
To the best of the author's knowledge, only one article has been 
published on neutron depth dose equations. In this article, Glover [46] 
has fitted exponential equations to the central axis depth dose data of 
Lawson et al. [lO]. The general form of equation used is shown by equa-
tion 16. 
P = 100(1 - (1 - exp(- xy))n) . (16) 
° >y 
The constants \ and n were determined from experimental data for 
two field sizes at a source-to-skin distance of 76 cm. It was found that 




This chapter contains a review of the information available for 
use in planning a study of the dose distribution produced in tissue by 14 
MeV neutrons. A summary of the techniques of dosimetry, collimation and 
shielding suitable for fast neutron therapy is given. This, is followed by 
a review of the available depth dose information related to 14 MeV neutron 
therapy. 
Dosimetry Methods 
Several systems have been devised to resolve the absorbed dose into 
gamma and neutron components. A proportional counter system has been de-
veloped by Hurst [47] for the determination of absorbed dose in tissue 
from fast neutrons while discriminating against gamma rays. This instru-
ment has a lower energy limit of about 200 keV for neutrons; therefore, 
additional measurements of the slow neutron component and gamma dose must 
be obtained. Usually the slow neutron dose is determined by use of a 
calibrated BF_ detector shielded with a layer of Cd. The dose due to 
neutrons in the energy range from the cadmium cutoff (0.4 eV) to 200 keV 
is not determined and the total neutron dose may be considerably under-
estimated [48]. 
The total dose due to mixed radiation fields may be obtained by 
use of small gas-filled tissue-equivalent ionization chambers. The ion-
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ization produced in the gas by charged particles originating in the cavity 
walls can be related to the absorbed dose in the wall material of the 
chamber by equation 17, which is known as the Bragg-Gray relation. 
D = JWS/100 , (17) 
where 
D = absorbed dose (rads) 
J = number of ion pairs formed per gram of gas 
W = average energy in ergs expended per ion pair formed by ioniz-
ing particles crossing the chamber 
S = effective value of the ratio of the mass stopping power of the 
wall material to that of the cavity gas for the ionizing 
particles. 
This relationship can be applied only if the following conditions 
are met. 
a. The cavity must be small so that there is a negligible effect 
on the distribution of secondary charged particles in the medium into 
which the cavity is introduced-. This implies that the linear dimensions 
of the cavity must be small in comparison to the range of secondary 
charged particles in the gas. 
bo The chamber walls must be thicker than the maximum range of 
secondary charged particles in the wall material so that all particles 
crossing the chamber originate in the wall material. 
c. The intensity of the primary radiation must be substantially 
constant over the chamber volume. 
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I t has been demonstrated by Fano [49] t ha t c o n d i t i o n (a) may be re laxed 
if the wal l and gas m a t e r i a l have s i m i l a r atomic composit ion and the value 
of S in equat ion 17 then becomes u n i t y . Condit ion (b) can be s a t i s f i e d 
for f a s t neutrons by making the wal l th ickness g r e a t e r than 2.5 mm. 
I o n i z a t i o n chambers have been cons t ruc ted with wal l and gas of 
t i s s u e - e q u i v a l e n t m a t e r i a l in order to ob ta in the t o t a l absorbed dose in 
t i s s u e due to any i o n i z i n g r a d i a t i o n . The chamber wa l l s a re cons t ruc ted 
of a g e l - l i k e m a t e r i a l which has the same atomic composit ion as so f t t i s -
sue . An explos ive mixture of hydrogen, oxygen, n i t r o g e n , and methane i s 
used as a f i l l i n g gas . I t i s necessary to use t h i s mixture in order to 
ob ta in a t i s s u e - e q u i v a l e n t gas which is not s o l u b l e in the chamber w a l l s . 
The composit ion of the chamber wal l s is given in Table 2. For obvious 
reasons t h i s ins t rument has been used only as a l a b o r a t o r y s t anda rd . 
P r a c t i c a l dosimetry i s done with t i s s u e - s u b s t i t u t e m a t e r i a l s such as 
t i s s u e - e q u i v a l e n t p l a s t i c s and gases . This change r e s u l t s in r ep l ac ing 
a la rge pa r t of the oxygen concen t ra t ion needed to s imula te sof t t i s s u e 
by carbon. Since the c ross s ec t ions of carbon and oxygen a re r a t h e r sim-
i l a r over a wide neut ron energy range, Rossi [23] has pointed out t ha t 
t h i s approximation of t i s s u e is j u s t i f i e d on the ba s i s of t h e o r e t i c a l 
pr inc i p l e s . 
At neutron ene rg ie s above 10 MeV n o n - e l a s t i c r e a c t i o n s with oxygen 
become important , being r e spons ib l e for about 15 pe rcen t of the absorbed 
dose due to 14 MeV neut rons [50J . Therefore , c o r r e c t i o n s should be con-
s ide red for n o n - t i s s u e composit ion of i o n i z a t i o n chamber dos ime te r s . 
Dose values obta ined with t i s s u e - s u b s t i t u t e chambers and s tandard t i s s u e -
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equivalent chambers have been found to agree within experimental error 
for neutrons with energy from 0.5 to 14 MeV energy after applying correc-
tions for the difference of atomic composition [23j. 
Some uncertainty in the absorbed dose determined by tissue-
equivalent ionization chambers arises when relating the charge collected 
to the dose. The energy lost by secondary charged particles in producing 
an ion pair has been found to vary somewhat with particle velocity L51,52] 
and particle type [52,53]. The variation with velocity is small. On the 
other hand, the change with particle type may be significant [47]. In 
general, W values for charged particles other than electrons and alpha 
particles are not well known and this introduces error in the value of 
the absorbed dose. A second problem is the recombination of ion pairs 
and the subsequent reduction of the measured value of J as a result of the 
high ion density produced by heavy recoil particles such as carbon and 
oxygen ions. 
The absorbed dose due to gamma rays may be determined by use of a 
second ionization chamber with low neutron sensitivity such as a graphite 
chamber filled with CO gas [48]. 
When the tissue-equivalent and graphite chamber are exposed to a 
mixed radiation field of neutrons and gamma rays the following relation-
ship may be used to obtain the absorbed dose due to neutrons and gamma 
rays [54 , 55 J. 
T = aN + by , (18) 
G = kN + by , (19) 
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where 
T = response of tissue-equivalent chamber in terms of 
roentgens of Co gamma radiation 
G = response of graphite chamber in terms of roentgens 
r 60, , . . 
of Co gamma radiation 
N and Y = absorbed dose in tissue due to neutrons and gamma 
rays, respectively (rads) 
a, b, and k = correction terms which are explained below. 
To obtain T and G each chamber must be calibrated with a known 
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Co gamma ray exposure. The instrument response (current, charge, volt-
age loss, etc.) to a mixed neutron and gamma ray field is multiplied by 
the appropriate calibration factor to evaluate T and G. 
Equations 18 and 19 contain several correction terms (a, b, and k) 
that are required due to the fact that T and G are expressed in terms of 
6n 
roentgens of Co gamma radiation. The first term (a) in equation 18 is 
necessary since equal amounts of ionization are not produced in tissue-
equivalent gas by equal absorbed doses of neutrons and gamma rays due to 
a difference in the W values for electrons and protons. Therefore, the 
portion of the ionization that is caused by neutrons must be adjusted if 
it is to be reckoned equivalent to that caused by an equal dose of gamma 
rays. The rad to roentgen factor (b) is also used to obtain consistent 
units on both sides of equation 18. The correction factor (a) has a 
value of 0.97 R per rad [54] and is given, by 
W 




b = rad to R conversion factor (1.03 R/rad) 
W = W value for protons 
P 
W = W value for electrons, 
e 
The factor k which appears in equation 19 is the ratio of the re-
sponse produced by exposing the graphite chamber to a neutron field that 
would result in the deposition of one rad in tissue to the response pro-
fin 
duced by exposing the graphite chamber to one R of Co gamma radiation. 
Values of k have been calculated for various neutron energies for 
the graphite chamber. At 14 MeV neutron energy this parameter has a 
value of 0.29 R/rad and decreases to 0.08 R/rad at 2.5 MeV neutron energy 
[55]. Thus, a reasonable knowledge of the neutron energy spectrum is re-
quired for use of this paired chamber system. Hurst [56] has indicated 
that uncertainties in the value of k result in an error of the order of 
± 10 percent or less in the neutron absorbed dose. Considerable error 
may result in the determination of the gamma dose component for mixed 
radiation fields with low gamma contamination. This error is a result of 
the fact that for this case the gamma dose component depends on the dif-
ference of two numbers which are about equal size. 
Many detector systems have been used for the determination of the 
gamma dose in the presence of neutrons. A Geiger-Mtiller gamma-ray dosi-
meter that is relatively insensitive to neutrons has been developed by 
Wagner and Hurst [57]. The k value for this instrument due to neutrons 
in the energy range from 0.68 to 4.2 MeV has been shown to be less than 
0.005 R/rad. Values of k due to higher energy neutrons have not been 
measured, but are estimated to be less than 0.015 R/radQ 
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Lithium f l u o r i d e thermoluminescent dos imeters may be used in p lace 
of a g r a p h i t e chamber for mixed f i e l d dos imet ry . Harshaw Chemical Comp-
any has developed LiF thermoluminescent dos imeters (TLD) which have the 
i so top i c composit ion shown in Table 4. 
Table 4 . I s o t o p i c Composition of TLD-100 and TLD-700 
Type Li Li 
(%)* (%)* 
TLD-100 7.5 92.5 
TLD-700 0.01 99.99 
* 
pe rcen t by weight 
The f i r s t dos imeter in Table 4 , TLD-100, responds to both thermal 
neutrons and gamma r a y s . A s t rong thermal neut ron response is produced 
by the Li(n,o/) H r e a c t i o n which has a c ross s e c t i o n of 950 barns for pure 
L i . The c ross s e c t i o n for t h i s r e a c t i o n has an average value of one barn 
for neutrons in the energy range from 10 keV to 15 MeV [ 5 8 ] . Due to the 
reduced c o n c e n t r a t i o n of Li in TLD-700 l i t t l e response is produced by 
thermal neut rons and the dosimeter is s e n s i t i v e p r i m a r i l y to gamma r a y s . 
Values of k have been determined for TLD-700 for neutrons with 
energy from 0.26 to 14.1 MeV [ 5 9 , 6 0 , 6 1 ] . An i nc r ea se in k from 0.005 a t 
0.26 MeV neu t ron energy to 0.17 a t 14.1 MeV neutron energy was repor ted 
[ 6 0 ] . Davy and O'Brien [62] observed changes in the Li conten t of TLD-
46 
700 (from 0.01 to 0.6 percent by weight) resulted in variations in the 
value of k. The range of Li percentage given above was obtained by 
mass analysis of TLD-700. 
The author of this thesis found that a plot of the k values given 
in reference 60 indicates a linear relationship between k for TLD-700 
and the energy of the neutrons as shown by equation 21. 
k(E) = mE + C , (21) 
where 
Response of TLD-700 produced by exposure to a 
neutron field which will deposit one rad in tissue 
k(E) = 
Response of TLD-700 produced by an exposure of 
ftd 
one R of Co gamma radiation 
E - energy of neutrons (MeV) 
m and c = slope and intercept constants. 
Davy and O'Brien [62] also presented theoretical values from which 
k can be obtained for neutrons with energy from 0.01 to 15 MeV. These 
calculations were based on the activation saturation model developed for 
scintillation detectors [63]. Theoretical curves were reported that re-
late the response of LiF thermoluminescent dosimeters produced by an 
exposure of unit fluence of neutrons to the response produced by an ir-
radiation which would result in the deposition of one rad in tissue. 
The present author has converted these data to k values for TLD-
700 and TLD-100 by use of fluence to dose conversion values given in 
ICRU Report 13 [64] and a rad to roentgen conversion factor of 1.03. A 
linear relationship similar to equation 21 was obtained between k(E) and 
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the neutron energy for both TLD-100 and TLD-700. 
In none of these studies was an attempt made to shield the LiF 
dosimeters from stray thermal neutrons. Slight thermal neutron contami-
nation of the fast neutron beam could cause uncertainty in the fast neu-
tron response values. This uncertainty could be quite large for TLD-100 
due to the higher concentration of Li in this dosimeter [65]. 
It has been found that LiF makes an excellent thermal neutron 
shield for TLD dosimeters [66,67]. This material has a high thermal neu-
tron cross section and does not emit secondary gamma rays upon neutron 
3 
capture. There is only one other material with these properties ( He) 
and being a gas, it is not suitable for neutron shielding [66]. 
Lithium fluoride thermoluminescent detectors have many properties 
that make them ideal for use as gamma ray dosimeters in depth dose studies 
for neutron therapy. Some of these properties are listed below: 
1. Low f a s t - n e u t r o n s e n s i t i v i t y . 
2. Simple l i n e a r response funct ion for neut ron ene rg i e s from 0.30 
MeV to 15 MeV. 
3. Compact size. 
4. Response that is independent of gamma ray energy over wide 
range (0.100 to 10 MeV). 
5. Approximately tissue-equivalent for gamma rays and X rays. 
6. Not affected by humidity, atmospheric pressure changes, and 
normal room temperature change. 
7. Very low dose fade with time (5.0 percent per year). 
8. Dose rate-independent to more than 1011 R/sec. 
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9. Wide dose range (few mR to 105R). 
10. Low thermal neutron sensitivity of TLD-700 and high sensitiv-
ity of TLD-100 permits determination of thermal neutron flux density. 
It was for these reasons that LiF dosimeters were chosen for use 
in this depth dose study. Probably the most accurate method for measure-
ment of the total dose due to neutrons and gamma rays is by use of tissue-
equivalent ionization chambers. For clinical trials of fast neutron ther-
apy, long-term consistency and repeatability of measurements may be more 
important than absolute accuracy of the dosimetry system. It has been 
estimated by Bewley et al. [68] that the systematic error in the dosim-
etry system mentioned above is less than ± 20 percent while the error in 
relative dose levels is unlikely to be more than 5.0 percent. 
Shielding and Collimation 
Several fast neutron collimators and shields have been constructed 
for use in tumor therapy with neutrons produced in cyclotrons using the 
9 10 
Be(d,n) B reaction [68,69,70]. Large thicknesses of hydrogenous mater-
ials were employed to attenuate the neutron flux. Only stationary hori-
zontal beams were produced and no attempt was made to provide beam direc-
tional control due to the weight of the source and shield. 
A lower weight and more compact shield can be produced by use of 
a composite shield [16,34,71]. An inner layer of iron or mild steel is 
used to degrade the energy of fast neutrons emitted by the source. Iron 
has a large cross-section for inelastic scattering of 14 MeV neutrons and 
on the average the neutron energy is reduced to below one MeV per reaction. 
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A relaxation length of about 8.5 cm has been reported [16,32] for this 
mechanism of removal of fast neutrons. Therefore, a 26 cm layer of iron 
would reduce the 14 MeV neutron flux by a factor of 95 percent. Iron is 
relatively ineffective as a shielding material for slower neutrons so a 
second layer of hydrogenous material, for examply polyethylene, is used 
to slow and capture the degraded neutrons. The neutrons now have a re-
laxation length of about five centimeters with respect to dose attenua-
tion in polyethylene. A thin outer layer of gamma shielding material may 
be necessary to reduce the capture gamma dose outside of the shield. 
Penetration of fast neutrons through various combinations of iron 
and polyethylene slabs and iron and water has been investigated [16,72]. 
Greene and Thomas [72] indicated that a combination of 20 cm of iron and 
20 cm of polyethylene produced optimum attenuation of 14 MeV neutrons in 
terms of the dose reduction produced by a shield of 40 cm total thick-
ness c An attenuation of the neutron dose of 96 percent was obtained by 
this shield. 
Little information on the design of 14 MeV beam collimators exists. 
Laafsdorf [73] has developed ray optics methods for collimation of one 
to three MeV neutrons. Application of this method to 14 MeV neutrons may 
be difficult since some of Langsdorf's arguments were based on isotropic 
scattering of neutrons in the laboratory system. The design of a colli-
mator system for 14 MeV neutron scattering experiments has been investi-
gated by Lent [16], Scattering from the walls of the collimator was 
analyzed in order to determine the intensity of scattered and 14 MeV 
neutrons in the beam. Collimator designs were reported for systems con-
50 
siderably larger than those envisioned for neutron therapy. For example, 
the total distance from the neutron source to the point where the beam 
emerged from the collimator (SDD) was 60 ft. 
A number of collimators have been constructed for use in depth 
dose studies of 14 MeV neutrons. Greene and Thomas [34] used tapered 
steel collimator inserts to produce various beam sizes. A homogeneous 
iron shield of 35.5 cm thickness was utilized to produce an attenuation 
of the neutron dose by a factor of 99 percent. A beam contamination of 
8.0 percent and 2.0 percent of the total dose was found for gamma rays 
and slow neutrons, respectively. 
Lawson, Clare, and Watt [10] utilized a polyethylene and lead 
shield to obtain depth dose measurements in tissue-equivalent phantoms 
for 14 MeV neutrons. Poor collimation resulted from this arrangement. 
At two centimeters depth the dose value changed only by a factor of 50 
percent when one moved from the geometrical edge of the beam laterally a 
distance of one centimeter. On the other hand, a change of 90 percent 
is seen for Greene's collimator for the same depth and lateral distance 
change. 
A shadow shield and collimator constructed of pressed hardwood has 
been used to obtain collimated beams of 14 MeV neutrons at the Lawrence 
Radiation Laboratory neutron generator [12,19]. This shield was in the 
form of a cube 60 cm on edge and was equipped with a removable collimator 
insert. 
Field sizes of 5 X 5 cm and 15 X 15 cm were investigated in a 
source study for neutron radiation therapy using this collimator. A 
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gamma contamination of 2.5 percent of the total absorbed dose was found 
for the smaller field and 8.2 percent for the larger field. 
A composite iron-polyethylene collimator and shield is being con-
sidered for use in a clinical trial of 14 MeV neutron therapy by Brennan 
[74]. The shield is designed to give one percent dose transmission and 
will have a total weight of less than 500 lb. The target housing is 
80 cm thick of which 20 cm is steel. To the best of the author's know-
ledge a test of the collimation properties of this proposed system or a 
similar one have not been made. 
Depth Dose Data 
Only meager depth dose information exists for collimated 14 MeV 
neutrons. Greene and Thomas [34] have obtained central-axis depth-dose 
values by use of small tissue-equivalent ionization chambers and a Hurst 
proportional counter. The portion of the total dose due to gamma rays 
was measured roughly by use of LiF dosimeters. It was not indicated 
that corrections were made for the fast neutron response of the LiF dos-
imeters. The phantom used for these measurements was made of Lucite with 
a 300 mm thick front wall. Its dimensions were 30 X 30 X 30 cm and it 
was filled with water [75]. Central-axis depth-dose data were acquired 
for four field sizes at 50, 75, and 100 cm source-to-skin distance. All 
fields were square and the size ranged from 5 x 5 cm to 40 x 40 cm. 
For treatment of deep abdominal and chest tumors, the 50 percent 
depth dose along the central axis should occur at about 10 cm or deeper 
[13]. With this depth dose distribution, it is possible to obtain a 
lower skin dose than the dose to the treatment volume. None of the depth 
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dose curves obtained by Greene at a target-to-skin distance of 50 cm met 
this requirement since the 50 percent depth dose occurred at 8.0 cm. In-
creasing the target-to-skin distance to 75 cm results in a 50 percent 
depth dose at 10 cm for field sizes of 7.5 X 7.5 cm and larger. 
Lawson, Clare^ and Watt [10] produced isodose plots for a 5.6 cm 
diameter field and a 16.4 cm square beam for an elliptical tissue-
equivalent phantom. Beam definition for these experiments appears to 
have been poor. It is difficult to detect the geometrical limit of the 
beam by examination of the isodose curves. Reasonable agreement was ob-
tained [76] between the central-axis depth-dose values of Greene and 
Thomas and the data of Lawson et al. 
Goodman and Koch [12] have obtained isodose distributions due to 
14 MeV neutrons for a 5 X 5 cm and 15 X 15 cm field at a target-to-skin 
distance of 125 cm. A 35 x 35 X 35 cm cubical phantom filled with 
tissue-equivalent fluid was utilized. The 50 percent depth dose occurred 
at 10 cm for the small field and 12.6 cm for the large field. Calcium 
fluoride thermoluminescent dosimeters were used in conjunction with 
tissue-equivalent ionization chambers to obtain the absorbed dose due to 
gamma rays and neutrons. 
Jones, Snyder, and Auxier [77] have used Monte Carlo techniques 
to calculate depth dose distributions in standard man tissue for a 14 MeV 
neutron beam of 5.0 cm diameter. The phantom assumed for this study was 
a right circular cylinder of diameter 30 cm and height 60 cm with the 
neutron beam incident perpendicular to the axis of the cylinder. It was 
found that the depth dose distribution for this beam was similar to the 
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broad beam case, but showed a more rapid decrease of dose with depth. 
Wilkie [20] has also calculated dose distributions in tissue by 
use of the Monte Carlo method for 14 MeV neutrons. Only the dose due to 
recoil nuclei was considered in his study. Isodose data were presented 
for neutron beams of size 5.0 cm and 10.0 cm diameter at a source-to-skin 
distance of 125 cm. Perfect beam collimation was assumed. An elliptical 
phantom having dimensions of 30 cm major axis and 20 cm minor axis and 
height of 60 cm was assumed. Broad beam depth dose distributions wer--
reported for homogeneous and heterogeneous phantoms. 
Dose values at the air-tissue interface of a tissue-equivalent 
phantom were obtained by Goodman and Koch [12] by use of ionization cham-
bers. Figure 7 is a plot of the ionization current measured at points 
near the surface of the phantom. As can be seen from equation 17, the 
degree of ionization produced by radiation is directly proportional to 
the dose. Therefore, a plot of the dose values near the surface of the 
phantom will have the same form as the curve shown in Figure 7. It has 
been concluded that the superficial layer of skin (to a depth of 0.5 mm) 
is the most important as far as the skin reaction to radiation is con-
cerned [78]. Thus, a skin sparing effect was observed for 14 MeV neutrons 
in the sense that the first few mm of skin received a lower dose than 
deeper layers. 
The position of maximum dose was found to be at 2.7 mm and the 
dose decreased by a few percent in going from a depth of 2.7 mm to the 
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Figure 7. Build-up Curve for 14 MeV Neutrons (from re fe rence 12) 
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Dose distributions for 14 MeV neutrons have been obtained experi-
mentally by Poston [79] at the bone-tissue interface. Percent dose values 
were determined in tissue and bone for points near the interface to a dis-
tance of two centimeters from the interface. 
Summary 
Depth dose information has been determined for only two field 
sizes at the SSD which has been recommended for 14 MeV neutron therapy. 
These distributions were based on the total dose in a cubical phantom 
and the gamma dose component was not determined for points off the cen-
tral axis. Dose distributions due to collimated beams of 14 MeV neutrons 
at a SSD of 125 cm have not been obtained by measurements in phantoms 
similar to a human in size and shape. No corrections for bone and lung 
tissue have been reported for collimated beams of 14 MeV neutrons. 
One attempt [46] has been made to express the percent dose along 
the central axis as a function of the irradiation conditions such as 
field size and depth. The empirical equation was fitted -to data obtained 
at a SSD smaller than that which may be used for fast neutron therapy. 
No attempt was made to establish a depth dose equation for points off the 
central axis. The use of a composite iron-hydrogenous material shield 
and collimator has been suggested for neutron radiotherapy, but no test 
of the degree of collimation produced by such a system has been made. 
Based on this lack, of information, needed for 14 MeV neutron ther-
apy planning, the objectives listed at the end of Chapter I were adopted 
for this study. 
CHAPTER IV 
INSTRUMENTATION AND EQUIPMENT 
From the information presented in Chapters II and III it was 
concluded that the objectives listed at the end of Chapter I could best 
be accomplished by utilization of the following instruments and equip-
ment. An iron-paraffin shield and collimation system was employed in 
conjunction with a commercial neutron generator to produce beams of 14 
MeV neutrons, Dose distributions were obtained for both homogeneous and 
heterogeneous phantoms by the use of a paired dosimeter system consist-
ing of small ion chambers and LiF thermoluminescent dosimeters. The 
performance of this paired dosimeter system was evaluated by the utiliza-
tion of a paired ionization chamber system and miniature tissue-equivalent 
ionization chambers. A description of the instruments and equipment used 
in this study occupies the remainder of this chapter. 
Ionization Chambers 
The dosimeters used to obtain the total dose due to neutrons and 
gamma rays for this depth dose study were tissue-equivalent ionization 
chambers. Small cylindrical chambers fabricated of conducting tissue-
equivalent plastic were utilized for the majority of the depth dose 
measurements and miniature Sievert type chambers [80] were employed to 
investigate wall-gas corrections for the cylindrical chambers. The 
cylindrical chambers will be referred to as "Type A chamber" and the 
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miniature Sievert chamber will be designated "Type B" in the discussion 
that follows. 
Figure 8 shows the general form of the Type A chamber and the 
holder used with this chamber. The sensitive volume of this chamber was 
0.53 cm3 and it was filled with air at atmospheric pressure for depth 
dose measurements. Since it was necessary to submerse the chambers in 
tissue-equivalent liquid for dose measurements, water-tight containers 
were constructed of tissue-equivalent plastic to protect the chambers. 
A combined chamber-wall plus holder-wall thickness of 3.0 mm resulted 
from this arrangement. Thus, an equilibrium thickness of tissue-equiva-
lent plastic surrounded the gas volume of each chamber [6,78], 
Total dose values were determined by measuring the voltage change 
produced by ionizing events in the sensitive volume of the chamber. 
Voltage measurements were obtained with a standard deviation of ± 1.0 
percent by use of a Keithley 610 B electrometer. The voltage change (AV) 
produced by exposing the chamber to radiation was determined by use of 
equation 22. 
AV = ((Vx + V3)/2) - V2 , (22) 
where 
Vx = voltage of fully charged chamber before exposure 
\I2 = voltage of chamber after exposure to radiation 
V3 = voltage of fully charged chamber after exposure. 
The voltage of the fully charged chamber was determined before and 
after the irradiation for the following reasons. First, these voltage 
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values can be used to establish the average voltage of the fully charged 
chamber. Second, any change in the capacitance of the chamber due to 
breakage or movement of the insulators can be detected by a change of V1 
or V3. Third, gross leakage due to contamination of the insulators by 
moisture or dirt can readily be detected by failure of the chamber to 
recharge. 
Calibration factors were determined for each chamber by exposing 
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the chamber and a Victoreen "R chamber" to a 70 millicurie Co source. 
The source was in the form of a small cylinder 0.63 cm in diameter and 
1.89 cm long. A light weight Styrofoam frame was used to position the 
source and chambers at a height of one meter above the floor of the cali-
bration room. All exposures were made in air with the chambers placed at 
a distance of 30.5 cm from the source. Figure 9 is a calibration curve 
obtained for a Type A chamber using the procedure outlined above. As 
can be seen from this curve, the voltage loss is directly proportional to 
the exposure in the range 0.0 to 1.0 R. All depth dose measurements were 
obtained on this portion of the curve. The Type A chambers all had cali-
bration factors of about 0.550 R/volt. 
The reproducibility of dose measurement was determined for each 
chamber by exposing the chamber repeatedly to a known dose of gamma 
radiation. Twenty separate irradiations produced the results shown in 
Table 5 for a Type A chamber. None of the chambers exhibited a standard 
deviation exceeding ±4.0 percent for an exposure of 0.36 R and the ma-
jority of the chambers had a standard deviation of ± 3.0 percent or less. 
Similar results were obtained using 14 MeV neutrons and repeating the 
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irradiation ten times. No dose rate effect was noted for the Type A 
chambers when the gamma exposure rate was varied by a factor of 20 nor 
were any dose rate effects observed for 14 MeV neutrons over the range of 
dose rates used. 
Table 5. Reproducibility of Type A Chamber 
Run AV AV - AV* [AV - AV]2  
(volt) (volt) (volt)2 
1 0.66 -0.006 0.000036 
2 0.67 0.003 0.000009 
3 0.68 0.014 0.000196 
4 0.69 0.024 0.000576 
5 0.66 -0.006 0.000036 
6 0.66 -0.006 0.000036 
7 0.67 0.003 0.000009 
8 0.65 -0.016 0.000256 
9 0.65 -0.016 0.000256 
10 0.66 -0.006 0.000036 
11 0.68 0.014 0.000196 
12 0.66 -0.006 0.000036 
13 0.67 0.003 0.000009 
14 0.65 -0.016 0.000256 
15 0.65 -0.016 0.000256 
16 0.66 -0.006 0.000036 
17 0.68 0.014 0.000196 
18 0.67 0.003 0.000009 
19 0.66 -0.006 0.000036 
20 0.66 -0.006 0.000036 
AV = 0.666 volts 
NOTE: Dose = 0.36 roentgens. 
The standard deviation as derived from Table 5 is given by 
. , [AV - Ay]2 _ ± 0^52 = ± Q o n v o U s 
\j N - 1 19 
where 
AV = voltage loss of ionization chamber in each run and 
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AV = average voltage loss of ionization chamber. 
The directional dependence of Type A chambers was investigated by 
irradiation of several chambers enclosed in waterproof containers at vari-
ous angles to the incident beam. Figure 10 is a polar diagram of the re-
sult of this test. Slightly less directional dependence was noted when 
several of the chambers were exposed in a water phantom. The in-phantom 
results are shown in Figure 10 by dotted lines. Similar results were ob-
tained for the directional response to fast neutrons. 
All Type A chambers exhibited small voltage losses due to insula-
tor leakage. As many as 15 chambers were exposed to radiation at the 
same time when depth dose data were obtained. In general, a time of one 
hour was required between the exposure and the voltage measurement of the 
last chamber. No detectable leakage losses were observed for a one hour 
period. A 24 hour leakage loss of 3.0 percent was typical of all Type 
A chambers. 
Miniature Sievert ionization chambers were used to investigate 
corrections for the wall-gas mismatch of the Type A chamber. Each of 
these Type B chambers was 5.0 mm in diameter and 20.0 mm in length and 
had a sensitive volume of 20 mm3. The sensitive volume of the chamber 
was filled with tissue-equivalent gas and the chamber was placed in a 
gas-tight holder. A total thickness of 3.0 mm tissue-equivalent plastic 
surrounded the gas volume, resulting in charged particle equilibrium for 
14 MeV neutrons. 
Table 6 shows the results of irradiation of Type A and Type B 







Figure 10. Directional Response of Type A Chamber 
in Waterproof Container 
64 
tissue-equivalent liquid was used at a source-to-skin distance of 20.0 cm 
for these measurements. The agreement between the air filled Type A 
chamber and the tissue-equivalent was that expected from the experimental 
errors involved. Therefore, wall-gas corrections were neglected subse-
quently for the Type A chambers. 
Table 6. Response of Type A and B Chambers 
to 14 MeV Neutrons in Terms of Co 
Gamma Ray Calibration 
Depth Dose Dose 
(cm) Type A Chamber Type B Chamber 
(equivalent 60Co R) (equivalent 6QCo R) 
1.5 0.81 0.83 
7.5 0.48 0.45 
12.5 0.35 0.35 
22.5 0.13 0.12 
A second test was initiated to determine if a significant correc-
tion was needed for the air filling of the Type A chamber. A 50.0 cc 
spherical tissue-equivalent ionization chamber flushed with tissue-
equivalent gas at a flow rate of six cubic feet per hour was used for 
this test. The spherical chamber and Type A chambers were exposed in 
air to a broad beam of 14 MeV neutrons. Once again no detectable differ-
ence in the response of the two chambers was noted. 
Paired Chamber 
A paired system of a tissue-equivalent and a graphite ionization 
chamber was employed for fast neutron calibration of the LiF dosimeters 
and evaluation of the Type A chambers. With this system it is possible 
to obtain the gamma ray dose and the neutron dose in a mixed radiation 
field by use of the method outlined in Chapter III. 
Each of these chambers had a 50.0 cc spherical sensitive volume 
and a wall thickness of 0.6 mm. Tissue-equivalent gas or C0? was used to 
flush the chambers during measurements at a flow rate of six cubic feet 
per hour. To obtain saturation conditions, a voltage of 1350 volts was 
applied to the center electrode of each chamber. Two Keithley 410 Micro-
Microammeters were used to measure the current produced by ionizing 
events in each chamber. 
Calibration factors were obtained for the chambers by exposing the 
fiCl 
chambers to Co gamma radiation in a manner similar to that described 
for the Type A chambers. A response of 3.42 X 10"£ R/min/amp was found 
for the tissue-equivalent chamber and 2.46 X 10"£ R/min/amp for the 
graphite chamber. The performance of the paired chamber system is shown 
in Table 7 for two fast neutron sources. The same neutron generator was 
used to obtain the reported [81] and observed values shown in Table 7. 
A five-curie PuBe neutron source was employed to obtain the observed value 
and a one-curie PuBe source was utilized in obtaining the reported values 
[82] shown in Table 7. The reported neutron dose for the PuBe source was 
obtained by multiplication of the value given in reference 82 by a factor 
of five. 
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Table 7. Dose Measurements with Paired Chambers 
Neutron Source Observed Reported Ref, 
* * 
Y Dose Neutron Y Dose Neutron 
Dose Dose 
(%) (rad) (%) (l^d) 
14 MeV Neutron 4 1.08 7 0.935 81 
Generator 
PuBe 5 Ci 8 0.0930 10 0.0887 82 
Percent of total dose 
Thermoluminescent Dosimeters 
Tissue-equivalent ionization chambers respond to both neutrons and 
gamma rays. It is desirable to resolve the total dose indicated by ioni-
zation chambers into gamma and neutron components. This allocation of the 
total dose can be facilitated by use of thermoluminescent dosimeters. 
Extruded lithium fluoride dosimeters (TLD-700) purchased from the 
Harshaw Chemical Company were used with the Type A ionization chambers to 
determine the neutron and gamma ray dose in liquid tissue-equivalent phan-
toms. Lithium fluoride TLD-100 obtained from the same supplier was used 
to obtain the thermal neutron dose. Both types of dosimeters were in the 
6D 
form of 1/8" X 1/8" X 0.035" chips. The Co gamma ray response of TLD-
100 and TLD-700 was determined using the same procedure as that used for 
the calibration of the Type A chambers. These gamma ray calibration fac-
tors were measured with a standard deviation of ± 6 percent using a com-
mercially available (Harshaw Model 2000) thermoluminescence analyzer. 
The magnitude of the radiation-induced response of the LiF dosimeters was 
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obtained by integrating the output from the photomultiplier tube of the 
analyzer. Glow curves of time versus luminescence were also recorded for 
each dose measurement. A 30 second heating cycle in which the dosimeter 
o 
was heated to 240 C was utilized to stimulate the emission of light from 
the dosimeter. 
Dry nitrogen flowed through the heating chamber at a rate of five 
cubic feet per hour to eliminate light produced by heating the dosimeters 
in the presence of oxygen. The dosimeters were annealed by heating to 
o o 
400 C for 15 minutes followed by two hours at 100 C to suppress the low 
temperature traps. 
Depth dose measurements and calibration determinations were made 
with the dosimeter enclosed in LiF shields of wall thickness of 0.4 cm. 
These shields were used to eliminate the strong response of TLD-100 to 
slow neutrons and to reduce the slight response of TLD-700 to slow neu-
trons. An attenuation of the thermal neutron flux of about 1000 times 
was obtained with this thickness of LiF. 
Thermal neutron response curves were established for TLD-100 by 
using a calibrated five-curie PuBe neutron source surrounded by 10.2 cm 
of paraffin. This arrangement produced a thermal neutron flux of 2.20 
X 10 n/cm /sec at the surface of the moderator. Gold foils with and 
without cadmium shields were used to establish the thermal neutron flux. 
A cadmium ratio of 5.9 was established from the foil measurements. For 
fi 
calibration, the dosimeters were irradiated with and without LiF shields 
for periods ranging from 2.0 hours to 16.5 hours. 
In order to evaluate the absorbed dose due to neutrons and gamma 
rays, values for k are needed for the LiF dosimeters. These values 
were established for a number of neutron energies. Table 8 presents the 
results obtained and the various neutron sources used for this measure-
ment. The paired chamber system described in this chapter was used to 
establish the total dose, neutron dose, and gamma dose for all neutron 
sources but the cyclotron sources. Neutron and gamma absorbed dose values 
were supplied by the Radiological Physics Group at each location. The 
neutron and gamma doses were obtained by the use of paired- ionization 
chambers. The gamma dose was also verified by LET spectrum measurements 
at the Texas A & M Cyclotron and by the use of film at the Hammersmith 
Cyclotron. 
Each response value represents the average of at least six dosim-
eter readings. The dosimeters were exposed to a neutron dose of two to 
five tissue rads of fast neutrons. All dosimeters were shielded with 
one-eighth inch of LiF in order to eliminate thermal neutrons. 
Response values obtained for the LiF dosimeters used in this study 
were of the same magnitude as values reported in the literature. Figure 
11 is a comparison of reported and observed values of the fast neutron 
response of TLD-100 and TLD-700. The experimental uncertainty indicated 
for the values obtained from this work was based on the precision of the 
TLD reader system and error due to statistical variations in the current 
values obtained from the paired chamber system. The lines shown in Fig-
ure 11 were based on a least-square analysis of the k values obtained 
in this study. 
Table 8. Values of k for TLD-100 and TLD-700 Obtained in This Study 
Neutron Source Location Neutron 
Energy 
(Mev) 
Gamma k k 
Contamination TLD-700 TLD-100 
(70 total dose) (R/rad) (R/rad) 
Neutron 
Generator 























































Neutron Energy (MeV) 
Figure 11. Comparison of k Values for TLD-100 and TLD-700 
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All values cited from the literature were converted from R per 
neutron/cm2 to R/rad using values obtained from reference 64, except the 
values given by Wingate and co-workers [60] and Bewley and Parnell [27]. 
Based on values obtained from this study, the value of k for TLD-700 was 
expressed as a linear function of the neutron energy (E) as shown by 
equation 24. 
k(E) = 0.012 E + 0.010 , (24) 
where 
E = neutron energy in MeV. 
Neutron Source 
Neutrons were produced by a Texas Nuclear Corporation Model 9999 
generator located at the DOSAR facility at the Oak Ridge National Labora-
tory. Depth-dose measurements and a portion of the calibration of the 
LiF dosimeters were performed using this neutron source. Accelerating 
voltages up to 200 kilovolts and beam currents greater than 1.5 mA were 
employed to produce neutrons. 
Neutrons of approximately 14.7 MeV energy were generated by the 
3 4 
H(d,n) He reaction by bombarding a thin tritium target with deuterons. 
A thickness of 0.470 cm of brass and 0.80 cm of water must be traversed 
by neutrons emerging from the target holder. The target contained 1.86 
Ci/crrf of tritium deposited in a thin layer (5. 0 mg/cm ) of titanium 
evaporated onto a copper disc 0.025 cm thick. The active area of the 
target was about 2.54 cm in diameter. The deuteron beam was focused on 
a spot 1.0 cm in diameter near the center of the target. Target cooling 
was achieved by a flow of water behind the copper backing. 
Neutrons of energy from two to three MeV were also obtained from 
2 3 
this generator employing the H(d,n) H reaction. Accelerating voltage 
and beam currents similar to those indicated for the DT reaction were 
2 3 
used. Targets were prepared for the H(d,n) H reaction by bombardment 
of a thin aluminum foil with a beam of deuterons. 
A modified Hansen-McKibben long counter [87] located 7.0 meters 
from the target of the neutron generator was used for normalization of 
the depth dose measurements. Neutrons were detected by a BF_ propor-
tional counter 1.5 cm in diameter and 37 cm long. The BF~ tube was 
mounted axially in a cylindrical paraffin moderator 22.5 cm in diameter 
and 37 cm long. It has been found by Auxier and co-workers [88] that 
this modified long counter is relatively insensitive to changes in neu-
tron energy. It was reported that the counts produced per neutron 
changed by a factor of about 18 percent over the neutron energy range 
0.5 to 4.0 MeV. The standard deviation produced by random variation of 
the neutron monitor was estimated by exposing several Type A chambers in 
a fixed position to repeated neutron exposures and comparing the read-
ings of the long counter with the chamber voltage changes. An increase 
of the standard deviation of ± 0.5 percent over that expected for the 
Type A chambers (±3.0 percent) was attributed to variations in the long 
counter readings. 
Collimator 
A collimator and shield somewhat similar to the ones suggested for 
neutron therapy were used to produce neutron beams of various sizes. The 
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major difference between the proposed collimator and the one utilized in 
this study was the fact that, in this study due to space limitations 
near the neutron generator, shielding material could not be placed com-
pletely around the target. The shadow shield system shown in Figure 12 
was employed to produce beams of field size from 7,5 x 7.5 to 18.4 x 18.4 
cm at a source-to-skin distance of 125 cm. The shield was designed so that 
the target of the neutron generator could be placed 8.0 cm within the 
paraffin cube. This arrangement provided shielding for neutrons leaving 
the target at angles greater than 90 and tended to reduce room scatter. 
The shield was equipped with a removable collimator insert and the colli-
mator opening had tapered sides which projected on the edges of the 2.54 
cm diameter target. A cast iron cylinder of 19 cm diameter and 16.4 cm 
length was placed adjacent to the target holder. The iron cylinder was 
imbedded in a paraffin parallelepiped 75 cm long, 75 cm wide, and 70 cm 
high. The center line of the collimator was located 0.96 meter above the 
floor of the accelerator room. 
Phantoms 
Two phantoms were constructed for the depth-dose study. One of 
these was a Plexiglas cube 35 X 35 X 35 cm with 6.0 mm walls. A rigid 
plastic frame was used to position the ionization chambers and LiF dosim-
eters for dose measurements. This phantom was filled with tissue-equiva-
lent liquid suggested by Goodman [25]. 
The other phantom was an elliptical cylinder with a major axis of 
32 cm and a minor axis of 21 cm and a height of 35 cm. Polyethylene 4.0 








Figure 12. Shadow Shield and Collimator 
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equivalent liquid was added to the phantom for depth-dose measurements. 
No bowing or distortion of either phantom was observed when they were 
filled with liquid. 
The effect of bone and lung on the dose distribution produced in 
soft tissue by neutrons was investigated by use of a cylinder of bone-
equivalent plastic (B-100) and a model of the lung constructed of granu-
lated tissue-equivalent plastic (A-150). The bone model was in the form 
of a cylinder 20 cm long and 4.0 cm in diameter. Figure 13- shows the 
outline of the lung phantom in a plane through the center of the beam. 
The dimensions used for the lung phantom were similar to those suggested 
by Fisher and Snyder [89], Thin plastic sheets of thickness 0.01 mm were 
used to fabricate the sides of the lung shaped container. The top and 
bottom of the container were closed with 0.6 cm thick plastic sheets. 
It was found that a density of 0.38 g/cm3 could be obtained by filling 
the container with granulated tissue-equivalent plastic. 
A thin Plexiglas frame was used to position the dosimeters and to 
also anchor the lung models in the elliptical phantom. Thin plastic 
tubes allowed the introduction of ionization chambers at three points 
within one of the lung models. 
Dosimeters could be placed at two centimeter intervals on a grid 
in a horizontal plane through the center of the neutron beam. The posi-
tion of the dosimeter frame was controlled by a row of nylon pins in the 
bottom and along the sides of each phantom. With this system, the posi-
tion of each dosimeter could be established to within 0.5 mm. 
o Ion Chamber Tube 
\ 
\ \ \ Gran^lated TE Plasti, 
Neutron Beam 




The procedure used to obtain depth dose data and the method em-
ployed to reduce these data to percent dose values is outlined in this 
chapter. 
Beam Alignment 
Accurate alignment of the center of the neutron beam with the cen-
tral axis of the phantom was achieved by measurement of the dose distri-
butions with Type A chambers. Vertical and horizontal lines of detectors 
were placed on the front and rear of the phantom to determine the location 
of the beam center with respect to the center of the phantom. It was usu-
ally necessary to make three or more beam traverse measurements for posi-
tioning of the phantom. 
Total Dose 
Total dose due to neutrons and gamma radiation was measured by 
exposing a horizontal row of Type A chambers at a given depth in the phan-
tom. As many as 15 Type A chambers spaced two centimeters apart were 
used for a single beam traverse. Traverse beam distributions were made 
at 2.0 cm depth intervals from 0.0 to 20.0 cm depth at a SSD of 125 cm. 
An investigation was made of the effect of placing 15 ionization 
chambers adjacent to each other. When dose values were compared for a 
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line of 15 detectors and a single detector, no difference was noted for 
the dose values at a given point in the phantom, indicating negligible 
perturbation of the radiation field. 
Central axis depth dose values were determined by use of Type A 
chambers that exhibited a standard deviation of 3.0 percent or less. 
The output of the neutron generator was determined for each exposure us-
ing the long counter described in Chapter IV. All dose values were 
corrected for temperature and pressure and normalized to a neutron output 
which would result in 1 X 105 long counter counts as shown by equation 
25. 





73) (760/P) (105 /LC) , (25) 
where 
D = total dose expressed in terms of Co calibration 
AV = voltage loss caused by exposure 
C = calibration factor for chamber in R/volt 
T = temperature (°C) 
P = pressure (Torr) 
LC = long counter counts for given irradiation. 
The performance of each Type A chamber was evaluated at intervals 
of about two weeks by exposing the chambers to three dose levels with a 
Co source. This procedure was adhered to for a period of about nine 
months during which depth dose data was taken. Leak tests were conducted 
on a daily basis when the chambers were being used for measurements. A 
third factor, the voltage of a fully charged chamber, was also utilized 
to detect any change in the performance of the ionization chambers. 
Gamma Ray and Neutron Dose 
Lithium fluoride thermoluminescent dosimeters (TLD-700) and Type 
A ionization chambers were used as a paired dosimeter system to obtain 
the gamma ray and neutron absorbed dose. Horizontal traverse runs were 
made with the dosimeters exposed at several points in the beam and out-
side. All TLD dosimeters were shielded with 0.3 cm of LiF to eliminate 
response due to thermal neutrons. The dose indicated by the TLD-700 
dosimeters (D ) was expressed in terms of the Co calibration factor 
as shown below. 
DTLD = (CTLD}(NC)(1(f / L C ) ' (26) 
where 
NC = response of TLD-700 obtained with TLD analyzer (nanocoul) 
C = Co gamma ray calibration factor for TLD-700 (R/nanocoul) 
LC = long counter counts. 
The neutron and gamma ray dose was then determined using the paired 
dosimeter concept. 
D = 0.97 N + 1.03 Y , (27) 
t 
DTLD = k N + l ' 0 3 y > < 2 8 > 
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where 
N = neutron absorbed dose (rads/lO5 long counter counts) 
Y = gamma absorbed dose (rads/lO5 long counter counts) 
k = average value of k (explained below). 
The average value of k was determined for TLD-700 based on the 
neutron spectrum measurements of Lucas and Quam [l9] for a 5 X 5 cm and a 
15 X 15 cm beam of 14 MeV neutrons in tissue and in air. This correction 
factor was calculated as 
k = I ' f(E)k(E)dE , (29) 
\ 
where 
f(E) = fraction of fast neutrons with energy between E and E + dE 
per unit energy interval 
E2 = maximum energy of neutron spectrum (15 MeV) 
E-L = minimum energy of neutron spectrum (2 MeV) 
k(E) = k value for TLD-700 at neutron energy E (given by equation 
24). 
It was found that at most the value of k was 2.2 percent less than 
k(15 MeV). This small difference between k and k(15 MeV) is a result of 
the low fraction of degraded neutrons and the decrease in neutron response 
of TLD-700 with neutron energy. A value of 0.18 R/rad was found for k 
using this method. Solving equation 27 and equation 28 for the neutron 
and gamma ray dose gives equation 30 and equation 31. 
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D - DmTT, 
N - ̂ _ p (30) 
0.18D - 0.97D 
v = — (31) 
Y 1.03 V ; 
Thermal Neutron Dose 
Due to the strong absorption of thermal neutrons in tissue, a 
large skin or near-skin dose may be deposited by a fast neutron beam that 
is contaminated with thermal neutrons. Therefore, thermal neutron flu-
ence measurements were made for each neutron beam in air and at several 
points within the phantom. The fluence values were then converted to 
dose due to thermal neutrons as explained below. 
Thermal neutrons were detected by use of TLD-100 with and without 
LiF shields. The thermal neutron fluence $ was calculated from the dif-
ference in the response of the shielded and unshielded dosimeters and 
normalized to 1 X 105 long counter counts. 
= C t h
( N Cu " N C s X
L C / l c P ) » <32) 
where 
C = thermal neutron calibration factor (7,15 X 10 (n/cm )/ 
nanocoul) 
NC = unshielded response of TLD-100 (nanocoul) 
NC = shielded response of TLD-100 (nanocoul) 
LC = long counter counts for given exposure. 
Fluence-to-dose conversion factors obtained by Auxier and co-
workers [90j for thermal neutrons were used to obtain the dose deposited 
by thermal neutrons in tissue D . , 
th 
Dth = K$ , (33) 
where 
K = fluence-to-dose conversion factor (rads/(n/cm2)) 
D , = dose deposited in tissue due to thermal neutrons (rads/lO 
long counter counts). 
Corrections for Patient Heterogeneity 
Several dose distributions were obtained for the purpose of estab-
lishing order of magnitude corrections for bone, lung and curvature of 
the patient. Dose distributions in soft tissue near bone were investi-
gated by use of a four centimeter diameter cylinder of bone equivalent 
plastic (B-100). The cylinder was located on the central axis of the 
cubical phantom at a depth of five centimeters with the axis of the cylin-
der in a vertical position. Traverse dose measurements were made in a 
horizontal plane at 0, 2, 10, 14, and 20 cm depth for a 18.4 X 18.4 cm 
beam. The central axis depth dose was measured at two centimeters depth 
intervals for the elliptical phantom filled with tissue-equivalent fluid. 
The phantom was irradiated with an 18.4 x 18.4 cm neutron beam. The depth 
dose values were compared with the central axis data obtained for the 
cubical phantom in order to determine the change in the dose distribution 
produced by the shape of the patient. 
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The lung models were then added to the elliptical phantom and 
depth dose data were obtained with the 18.4 X 18.4 cm beam centered on one 
of the lungs. 
Percent Dose, Gamma Dose Component, and Traverse Function 
For treatment planning the dose values are usually expressed as 
percentage of the dose at some reference point. These values are used to 
obtain percent dose values for complex treatment plans such as those based 
on the multifield technique. The actual dose delivered to various points 
in the patient can then be established by use of this dose distribution 
and a single dose measurement made at the reference point. The percent 
total dose P at depth y along the central axis was calculated as 
Dfc 




D = dose due to total radiation (neutron + gamma) at depth y 
along central axis 
Dg = total dose at depth of two centimeters along central axis. 
A discussion of the error involved in the determination of P is 
y 
given in Appendix A. 
The gamma dose component which represents the portion of the total 









P = percent of total dose at point (x,y) due to gamma radiation 
x >y 
Y D = dose due to gamma radiation at location (x,y) x,y 
D = dose due to neutron plus gamma radiation at (x,y). 
x ?y 
Equation 36 was utilized to calculate the traverse dose function 
F. 
F _ x , y 
o , y 
(36) 
where 
x = distance off central axis 
y = depth in phantom (constant for a traverse) . 
A summary of the sources of error in the gamma dose component and 




Collimation and Shielding 
In order to determine the properties of each beam used in this 
study, beam profiles were obtained at the position of the surface of the 
phantom. Figure 14 shows a beam profile for the 13 X 13 cm field at a 
source-to-skin distance of 125 cm. The traverse run made without the 
phantom in place will be referred to as an air traverse and is shown in 
Figure 14 by the dotted curve. The traverse dose distributions made with 
and without the phantom in place are of similar shape. On the other 
hand, the magnitude of the dose values measured with the phantom in place 
was about 10 percent greater than that obtained in air. It was found 
from TLD and Type A ionization chamber measurements that the majority 
of the radiation "backscattered" by the phantom was gamma radiation. The 
gamma dose component at the central axis increased from 4.0 percent in 
air to approximately 10 percent with the phantom in place. This in-
creased gamma dose was due to neutron capture and inelastic scattering 
reactions in the volume of the phantom irradiated. 
Table 9 is a summary of the beam properties of each field utilized 
in this study. As can be seen from this table, a beam sharpness of two 
to three centimeters was found for each beam and accounted for up to 30 
percent of the nominal beam size. Similar values were obtained from beam 
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Figure 14. Traverse Dose Functions in Air and at the Surface 
of the Phantom for the 13 X 13 cm Field 
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mean energy of 7.65 MeV and by Greene and Thomas [34] for 14 MeV neutrons. 
These values of beam sharpness were found to be quite large when compared 
fif) 
to those obtained from traverse dose functions for Co radiotherapy 
f\C\ 
beams. Values of the order of 0.5 cm or less were obtained for Co beams 
and accounted for 10 percent of the beam size. The neutron beams were 
found to be flat over approximately 70 percent of the beam width in air 
and then decreased to 10 to 15 percent of the central axis value a few 
centimeters outside of the beam. The fraction of the total dose due to 
thermal neutron contamination of the beam is quite low, being of the order 
of about one percent. 
Table 9. Properties of Neutron Beams in Air 
Y th 
Field Size f s p PY P 
Flatness Sharpness Geometrical Percent of Percent of 
Penumbra Total Dose Total Dose 
Due to y Due to Th. 
(cm) (cm) (cm) Neutrons 
7.5 X 7.5 0 .65 2 .5 0 .87 4 . 4 1.2 
1 1 . 5 X 11 .5 0 .70 3 .0 0 .87 4 . 3 0 .86 
13 X 13 0 .70 2 . 4 0 .87 5 . 1 1.3 
1 8 . 4 X 18 .4 0 . 7 1 2 . 8 0 .87 4 . 9 1.0 
The presence of the collimator and shield resulted in little in-
crease of the gamma ray dose component. A gamma contamination of approxi 
mately four percent of the total dose was obtained without the shield and 
values ranging from 4.4 to 5.1 percent were obtained with the shield in 
place. 
A measurement of the radiation reaching the phantom area due to 
room scatter and penetration through the shield was obtained by blocking 
the collimator opening with paraffin and exposing the ionization chambers. 
Dose levels of approximately eight percent of the open beam dose were 
found. Therefore, most of the radiation reaching points outside of the 
neutron beam did so by direct penetration through the shield and by room 
scatter. Measurements of room scatter have been made for the neutron 
generator used in this study by Stone and Thorngate [91]. It was con-
cluded that about five percent of the total dose was due to scatter of 
neutrons in the accelerator room. Based on these figures, the reduction 
in total dose produced by the shield was approximately 97 percent. 
Central Axis Depth Dose 
Central axis dose values were established by making measurements 
at two centimeter intervals along the center of the cubical phantom. 
Table 10 is a summary of the results of this series of measurements. 
Each total dose value represents the average of three measurements and, 
as shown in Appendix A, a standard deviation of ± 4.5 percent can be as-
signed to these values due to experimental error. The gamma dose compo-
nents may have a larger error due to the inherent inaccuracy of the paired 
dosimeter method. These gamma dose components could be a factor of two 
larger than the values shown in Table 10. 
All of the neutron beams investigated met the requirement for a 50 
percent depth dose at a depth of 10 centimeters or greater. This condi-
tion was met in terms of both total dose and neutron dose. As can be seen 
from Table 10, the dose at a given depth increased with field size as a 
Table 10. Central Axis Depth Dose Percentages for 14 MeV 




Field Size\7.5 x 7.5 








11.4 X 11.4 










8 65.5 67.9 70.8 72.4 
10 55.4 9 59.5 9 61.5 10 66.7 13 
12 45.7 49.1 52.0 56.0 
14 38.0 10 42.2 10 44.0 12 48.0 14 
16 30.5 34.5 39.3 39.2 
18 26.0 12 30.0 11 31.5 14 35.2 16 
20 22.1 26.3 27.0 29.4 








result of more scattered radiation reaching the central axis. Figure 15 
shows the effect quite clearly and can be used to compare some of the 
Monte Carlo calculations with values obtained from this study. The broad 
beam dose distribution reported by Auxier and co-workers [90] for 14 MeV 
neutrons was converted to percent total dose normalized to 100 percent at 
two centimeters depth. The same procedure was applied to values given by 
Jones and co-workers [77] to obtain the depth dose curve for a five centi-
meter beam. It is worth noting that both of the curves produced by the 
Monte Carlo technique have an infinite value for the source-to-skin 
distance. 
The broad beam depth dose values are considerably larger than the 
values found for the 18.4 X 18.4 cm field due to two factors. First, an 
infinite SSD would result in larger depth dose values because there is no 
reduction of dose due to inverse square attenuation. Secondly, the whole 
phantom was assumed to be irradiated for the Monte Carlo calculation and 
as a result more scattered radiation would reach the central axis causing 
the dose to be greater than that obtained for small beams. 
Wilkie [20] has reported neutron dose components based on Monte 
Carlo calculations for 14 MeV neutrons at an SSD of 125 cm. Figure 16 
can be used to compare Wilkie's neutron dose distributions with values 
obtained from this investigation. There is good agreement between the 
three dose distributions shown in Figure 16 in the sense that larger per-
cent dose values were obtained at a given depth as the field area was in-
creased from 25 cm3 to 225 cm2 . 
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Figure 16. Central Axis Dose Due to Neutrons ô 
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was relatively small (< 16 percent). Expressing the dose components in 
terms of the RBE dose as outlined below results in gamma dose components 
that are considerably smaller than those shown in Table 10. 
The neutron and gamma ray absorbed dose values determined in this 
study were converted to RBE dose by use of an RBE factor of three [4,13, 
15] for 14 MeV neutrons and one for gamma rays. Figure 17 shows the RBE 
dose obtained for neutrons and gamma radiation for a 13 X 13 cm field. 
Similar curves were found for the other field sizes utilized in this 
study. As can be seen, only a small portion of the total RBE dose is 
due to gamma rays. 
Traverse Dose Distribution 
Traverse dose distributions based on total dose due to 14 MeV 
neutrons are shown in Figures 18 and 19. Measurements supplied by Good-
man [92] for a 15 X 15 cm field are also shown in Figure 19 by dotted 
lines. A complete summary of all traverse measurements is given in Appen-
dix B. A beam sharpness of 2.8 cm was obtained from Goodman's data at 
10 centimeters depth and 5.0 cm for the 13 X 13 cm field utilized in this 
study. As expected, the beam width and beam sharpness increased with 
depth in the phantom for all fields. Figure 18 shows traverse dose dis-
tributions for several depths. As can be seen from these curves, there 
was also considerable increase in the dose outside of the beam as one 
goes from points near the surface to a depth of 20 cm. 
Figure 20 can be used to compare the traverse functions for 14 MeV 
, 60„ •,.. m l 6 0 „ r r . _. 
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Figure 17. RBE Dose for Neutrons and Gamma Rays (14 MeV Neutrons, 125 cm SSD, 
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Figure 18. Traverse Dose Functions for 11.4 X 11.4 cm Field 
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Figure 19. Traverse Dose Functions for Various Field Sizes 
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Figure 20. Traverse Dose Functions for Co Gamma Radiation 
and 14 MeV Neutrons 
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and are for a typical 10 X 10 cm field at 80 cm source-to-skin distance. 
All curves are normalized to 100 percent near the surface of the phantom. 
Smaller penumbra width and lower dose level outside the beam are ex-
hibited by the curves for gamma radiation at all depths. 
A traverse function for an X ray beam [34] of common clinical use 
is shown in Figure 21 for a depth of 10 cm in tissue. The neutron beam 
for the same depth exhibits superior beam flatness, penumbra width, and 
dose level outside of the beam. 
The gamma dose component was determined at several depths for 
points off the central axis. It was found that the gamma dose component 
Y (P ) was approximately constant in the beam area and increased as one 
x,y 
moves away from the edge of the beam. Values of the gamma dose component 
are given in Appendix B. It should be pointed out that the neutron re-
sponse values used for the LiF dosimeters outside the beam were too large 
since they were based on the average response in the beam. The average 
energy of the neutron field outside of the beam would be approximately 
seven MeV or less as a result of energy degradation by scattering. There-
fore, the values shown in Appendix B for the gamma component outside of 
the neutron beam have been over-corrected for neutron response. 
The only available data with which a comparison of the gamma dose 
component can be made are those reported by Jones et al. [77] for a five 
centimeter diameter beam. The gamma component for this beam was based 
on the dose due to (n,y) reactions. Gamma rays generated by inelastic 
scattering were not taken into consideration by Jones. In general, Jones' 
data showed an increase in the gamma contamination from about one to two 
11.4 x 11.4 cm Field of 14 MeV Neu-
trons, SSD = 125 cm (this study) 
1.00 
°--10 X 10 cm Field of X Radiation, 
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percent in the beam to approximately 25 percent for points 11.5 cm off 
the central axis. The fraction of the total dose due to gamma rays ob-
tained from Jones1 data showed little change with the depth at which the 
traverse distribution was determined. 
The gamma dose component obtained for the 7.5 X 7.5 cm field showed 
an increase from approximately 9.0 percent to 30 percent in going from 
points on the central axis to points well outside of the beam. This 
larger gamma dose component could be due to a number of factors such as 
the presence of gamma radiation generated in the accelerator room by cap-
ture and inelastic scattering of neutrons. The wide penumbra of the 
7.5 X 7.5 cm field would contribute to an increased gamma dose. On the 
other hand, perfect collimation was assumed for the five centimeter beam. 
Uncertainty in the calibration of the TLD dosimeters for neutrons and 
gamma rays could easily lead to a large positive systematic error. It 
has been indicated by Ritts [93] that inclusion of gamma rays produced 
by inelastic scatter can result in an increase of the gamma dose in tissue 
by a factor of two for the broad beam case. 
Depth dose data may be presented in a diagrammatic form by isodose 
plots. These diagrams are contours of equal dose values for points in a 
plane through the center of the beam. The dose distributions given in 
Appendix B were used to establish the isodose charts shown in Figures 22, 
23, 24, and 25. A falling-off of dose near the edge of the beam can be 
seen as can scattered radiation beyond the geometrical confines of the 
beam. The relatively high dose level of 10 to 20 percent of the central 
axis value at two centimeters depth for points approximately five centi-
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Figure 22. Isodose Contours Derived from Experiruer.tal Data in Table 14 for 
of 14 MeV Neutrons at an SSD of 125 cm 
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Figure 23. Isodose Contours Derived from Experimental Data in Table 15 for 11.4 X 11.4 cm 
Field of 14 MeV Neutrons at an SSD of 125 cm 
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Figure 24. Isodose Contours Derived from Experimental Data in Table 16 for 13 x 13 cm 
Field of 14 MeV Neutrons at an SSD of 125 cm o 
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Figure 25. Isodose Contours Der'ved from Experimental Data in Table 17 for 18.4 x 18.4 cm 
Field of 14 MeV Neutrons at an SSD of 125 cm o 
4> 
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meters outside of the beam is similar to that of therapeutic X ray beams. 
It would be desirable to reduce this dose component in order to minimize 
the dose to healthy tissue outside of the neutron beam. This could be 
accomplished by the use of improved shielding and collimation systems. 
The dose distributions of the four fields investigated are similar 
to those calculated by Wilkie [20] using the Monte Carlo method and assum-
ing perfect beam collimation. Depth dose percentages of 1.0 to 5.0 per-
cent were obtained by Wilkie for points approximately five centimeters 
outside of the neutron beams. The depth dose percentages obtained at the 
same points in this investigation are of the order of 10 to 20 percent as 
a result of the lower degree of beam sharpness and the presence of radia-
tion due to room scatter and penetration of neutrons through the shield. 
The general features of the isodose curves reported by Goodman and Koch 
[12] are also similar to the features of the dose distributions obtained 
in this study. 
Treatment Planning Equation 
For purposes of fast neutron treatment planning, using digital 
computers, it is desirable to obtain simple, accurate, and continuous re-
lationships between the percent absorbed dose at a given depth and the 
conditions of irradiation. The central axis data obtained for the four 
fields investigated in this study were successfully fitted to equation 14 
which was developed by Sterling and co-workers [38] for Co radiation. 
For 14 MeV neutrons the central axis depth dose (P ) takes the form 
o,y 
Pt = antilog[-0.0425 y + (0.0198 y - 0.0395) log(A/E) + 2.106] , (37) 
° »y 
where 
y = depth (cm) 
A = area field (cm2) 
E = perimeter of field (cm). 
Agreement between experimental and calculated values was found to 
be within 2.0 percent for the majority of the points along the central 
axis. In several cases the difference between the calculated and experi-
mental value was as much as 7.5 percent. 
A relationship similar to equation 37 was found for the central 
axis depth dose data reported by Greene and Thomas [34] for 14 MeV neu-
trons and also for values given by Bewley and Parnell [27] for cyclotron-
produced neutrons with a mean energy of 7.65 MeV. 
Based on this study and the central axis data reported by the 
groups mentioned above, the range of application of equation 37 for fast 
neutrons is for field sizes from 5 X 5 cm to 20 X 20 cm and for depths 
greater than two centimeters but less than 22 cm. It is therefore pos-
sible to express the central axis depth dose due to fast neutrons for all 
field sizes and depths of clinical interest in the form of a simple equa-
tion containing only four fitting constants. 
Traverse dose functions (F) were also established for the beams 
utilized in this work using methods developed by Sterling and co-workers 
[38] for Co radiation. It was found that each traverse distribution in 
Appendix B was sigmoid in nature and could be fitted to equation 15 but 
differed from the gamma radiation case in that two sigmoid curves were 
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required for each traverse distribution. Values of the fitting constants 
(o",(Ji) found for each traverse dose distribution are given in Appendix C. 
Agreement between observed and calculated dose values using these con-
stants in equation 15 was 5.5 percent or less. Some general trends in 
changes of the fitting constants can be seen from Appendix C. For ex-
ample, the values for a and \i for points in the beam area tend to increase 
with depth in the phantom and outside of the beam the fitting constant \i 
increases with depth. No general trend was seen for changes in a with 
depth for points outside the geometrical area of the beam. 
Combining equations 37 and 15, one obtains a general expression 
for the percent dose in a plane through the center of a cubical block of 
tissue irradiated with 14 MeV neutrons from a source located 125 cm from 
the surface of the block. 




exp ((*/D - ̂  dU/L)| 
^2TT a - _oo 2a2 
The range of application of equation 38 is for points such that 
2 s y ^ 20 cm and 0 ̂  l/L ^ 2. 
Corrections for Bone and Lung 
The distortion of soft tissue dose distributions due to the pres 
ence of bone and lung was determined in order to obtain realistic treat 
ment planning information. The traverse dose distributions shown in 
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Figure 26 and Figure 27 were all normalized to the dose obtained at a 
depth of two centimeters along the central axis without bone present. 
Values of the percent dose in bone were approximated by use of the follow-
ing technique. As suggested in ICRU Report 13 [64], the percent dose 
value measured at a depth of two centimeters in tissue with bone present 
was reduced by a factor of 1.26 to obtain the percent dose in bone at a 
depth of approximately three centimeters from the front surface of the 
phantom. Values of the dose received by tissue as compared to bone re-
ported by Ritts [93] were used to obtain the ratio 1.26. It was assumed 
that the percent dose in bone follows a simple inverse-square exponential 
relationship. A linear attenuation coefficient of 0.108 cm" has been sug-
gested by Wilkie [20] for bone. This value was used in obtaining the 
dotted curve shown in Figure 27 for points within bone. This portion of 
the curve is only an approximation of the percent dose in bone and at 
points less than 0.5 cm from the bone-tissue interface is at best a very 
rough approximation of the actual dose distribution. 
An increase of 7.0 percent in the dose level with bone as compared 
to the dose without bone was noted for the traverse run at two centimeters 
depth and also at the surface of the phantom. Both of these distributions 
were in front of the cylinder of bone-equivalent plastic. This difference 
in dose level was slightly greater than the statistical uncertainty ex-
pected for these measurements and occurred for all of the points near the 
bone cylinder. The higher density and different elemental composition of 
bone as compared to tissue may result in "backscattering" of neutrons 
causing the dose to tissue in front of bone to be increased. Within 
1 r 
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at a Depth of Two Centimeters o 
110 
ioo H °—Homogeneous Phantom 
•—With Bone Cylinder 
8.0 12.0 
Depth (cm) 
Figure Central Axis Dose Distribution With and Without Bone 
I l l 
experimental error (standard deviation of 4.5 percent) the dose distri-
butions for points behind the bone cylinder (depths of 10, 14, and 20 cm) 
were the same as the distributions found for the homogeneous phantom. 
This observation was supported by the experimental work of Poston [79] in 
which the conclusion was drawn that the upper limit of the dose given to 
tissue behind a bone-tissue interface is the dose in tissue in the absence 
of bone. Lawson [94] has made the same suggestion based on theoretical 
calculations. 
The gamma ray dose levels near the bone cylinder were similar to 
those measured in the cubical phantom without bone plastic. Further 
study of the dose distribution near bone should be undertaken since the 
possibility of increased dose due to backscattering of radiation has been 
demonstrated. 
Table 11 gives depth dose values for the central axis of the ellip-
tical and cubical phantom irradiated by an 18.4 X 18.4 cm beam. All per-
centages indicated in Table 11 were based on the total dose and were 
normalized to 100 percent at a depth of two centimeters for each field. 
In general, the dose levels were slightly less for the elliptical 
phantom with and without lungs as compared to the dose measurement in the 
cubical phantom. The gamma dose component for each phantom was the same 
within experimental uncertainty (± 8.5 percent) 
Depth dose data were also obtained with the 18.4 X 18.4 cm beam 
centered on one of the lungs. Dose measurements were obtained with and 
without lung in the phantom. Figure 28 shows results of this series of 
measurements based on neutron dose. Each curve was normalized to 100 
Table 11. Depth Dose Distributions in Cubical and Elliptical 
Phantom for 18.4 X 18.4 cm Field at an SSD of 125 
cm 
Depth Percent \ Pt 
o,y 
Pfc 
o,y Depth Dose \ 
(cm) Cubical Elliptical Elliptical 
y Phantom Phantom Phantom 
with Lung 
a) (%) a) 
2 100 100 100 
4 91.2 95.0 96.0 
6 84.5 79.0 78.2 
8 72.4 71.5 73.0 
10 66.7 63.0 57.3 
12 56.0 56.5 54.3 
14 48.0 44.2 43.7 
16 39.2 35.0 33.4 
18 35.2 33.3 37.0 
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percent at two centimeters depth with lungs present. Wilkie's Monte Carlo 
calculation [20] for broad beam irradiation of a 20 X 30 cm elliptical 
cylinder 60 cm high is also shown in Figure 28. Wilkie's curve falls 
above the curves for the 18.4 X 18.4 cm beam. These higher percent depth 
dose values could be due in part to the following factors. In the broad 
beam case the whole phantom was irradiated; therefore, more scattered 
neutrons and gamma photons would be present for points along the central 
axis of the beam than for the case of narrow beams such as the ones used 
in this investigation. 
The reduction of beam intensity due to inverse square effect would 
also result in lower depth dose values for the 18.4 X 18.4 cm beams as 
compared to the broad beam case. A decrease of depth dose by a factor 
of 14.4 and 25.8 percent at 10 and 20 cm depth would result from inverse 
square attenuation. Application of inverse square corrections to Wilkie's 
data results in percent dose values that are in reasonable agreement with 
the values obtained in this study. 
Based on these measurements there seems to be a higher dose in and 
behind lung tissue due to the lesser attenuation of the neutron beam by 
lung tissue. An increase of 12 percent was seen at 12 cm depth and 17 
percent at 18 cm when dose values with and without lungs were compared. 
This lower attenuation for lung is due to the reduced density of lung 
tissue as compared to that of soft tissue. 
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CHAPTER VII 
CONCLUSIONS AND RECOMMENDATIONS 
Conclusions 
An experimental investigation of the dose distribution produced 
in tissue by beams of 14 MeV neutrons with a source-to-skin distance of 
125 cm has been presented. The results of this study clearly show that 
beams of 14 MeV neutrons exhibit adequate penetration, beam flatness, and 
beam sharpness for radiotherapy. In tissue located outside the geometri-
cal confines of the beam, dose levels of magnitude similar to that of X 
ray beams used in radiotherapy are encountered. This situation would be 
acceptable for fast neutron therapy but it would be desirable to further 
reduce the radiation dose experienced by healthy tissue outside of the 
beam. Approximately 50 percent of the radiation dose near the surface of 
the patient is due to room scattering of neutrons. Therefore, complete 
shielding of the target would give considerable improvement of the dose 
distribution near the patient's skin. One of the most striking features 
of the neutron beam is the low gamma and thermal neutron dose components 
in air and within the geometrical area of the beam in tissue. 
The dose distributions obtained in this study are quite similar to 
the limited number of experimental distributions reported by other workers 
[34,12] for beams of 14 MeV neutrons. Reasonable agreement is also ob-
tained between dose distributions calculated by the Monte Carlo method 
_20,77,90] and the distributions determined in this investigation. 
It is concluded that the dose distribution in soft tissue can be 
expressed as the product of two simple functions. It appears feasible 
to utilize equations of this type in computer assisted therapy planning. 
It is also concluded that small corrections of the soft-tissue 
dose distribution are required to account for the presence of bone. On 
the other hand, large positive corrections must be utilized in adjusting 
the soft-tissue dose distribution to account for the decreased attenua-
tion occurring in the lungs. The dose received by soft tissue in front of 
bone appears to be increased by a factor of 7.0 percent compared with 
the dose at the same location without bone. This increased dose can be 
attributed to backscattering of radiation by bone. These observations 
are of importance since they can be used to convert the dose distribu-
tions obtained in soft tissue to those that would be obtained in a patient 
irradiated with a collimated beam of 14 MeV neutrons. 
Several conclusions can be drawn concerning the performance of the 
iron-paraffin collimator and shield used in this study. First, a satis-
factory shield size, weight, and dose attenuation near the edge of the 
beam can be obtained. Secondly, a major disadvantage of the shielding 
system is the relatively high dose level observed for points outside of 
the beam. Dose levels of approximately three percent of the dose at the 
center of the beam are obtained as a result of radiation transmitted 
through the shield. A whole body dose of this magnitude is unacceptable 
for fast neutron therapy. Thus, it will be necessary to use shielding 




Based on this study the following recommendations for future 
research in this area are made. For treatment planning for 14 MeV neu-
tron therapy, additional depth dose data are needed for many field sizes 
in the range of areas from 25 cm2 to 400 cm2. A detailed study of the 
dose distribution in tissue in front of bone should be undertaken in 
order to confirm the backscatter effect observed in this work. 
It is recommended that improved collimator and shield designs be 
developed. Both experimental and Monte Carlo methods should be used in 
order to establish optimum shield and collimator configurations. 
It is also recommended that improved fast neutron calibration of 
TLD-700 be obtained in order to reduce the uncertainty in mixed-field 
gamma, dose measurements. Accurate calibration could be obtained by use 
of tissue-equivalent proportional counters such as those developed by 
Rossi [95]. This instrument has excellent gamma discrimination in terms 
of absorbed dose and could be used to establish the neutron dose. 
To establish the average neutron response of TLD-700, neutron spec-
tral information is required. Monte Carlo programs should be developed 
for the purpose of calculation of the neutron energy spectrum in tissue 
for points within and outside of the neutron beam. Experimentally deter-
mined beam profiles should be used rather than assuming perfect collima-







The following definitions of terms associated with errors appearing 
in the research were adopted from reference 96 for use in this work. 
The term "experimental error" will be used to denote the uncertainty 
associated with an experimental value due to random fluctuations produced 
by factors such as personal judgment in reading an instrument scale. 
Error values used to denote the difference between a measured value and 
the "true" value of some quantity will be referred to as "systematic 
errors." Measurements with small experimental errors will be considered 
to have high precision. On the other hand, values with small systematic 
errors will be considered to have high accuracy. In the discussion that 
follows, the standard deviation, a, was used as an index to indicate the 
magnitude of the experimental error associated with a measurement. The 
terms standard deviation and experimental error were considered to be 
equivalent. The standard deviation, a, was defined as 
a = W ; , 
where 
x = arithmetic average of k measurements of the quantity x 
th 
x = value of n measurement. 
n 
Error in Percent Dose Values 
In order to establish the voltage change produced by exposing a 
Type A chamber to a given dose, the series of voltage measurements shown 
in Table 12 must be made. The standard deviation values shown in Table 
12 are based on repeated voltage readings of the Type A chamber using the 
Keithley 610B electrometer. 
Table 12. Errors in Voltage Measurements Required 
for Dose Determination 
Step Voltage Standard Deviation 
in Voltage 
(volt) (volt)  
Charge-read Vx ± 0.01 
Charge-expose- V2 ±0 .01 
read 
Recharge-read V3 ±0 .01 
The voltage change (AV) caused by the irradiation is obtained from 
equation 40. The term (Vx + V3)/2 is the average voltage of the fully 
charged chamber. 
Av = (<Vi + V3)/2) - V2 (40) 
The standard deviation in (AV) is given by the square root of the 
sum of the squares of the standard deviation in voltage V2 and (V1 + V3)/2 
as shown below. 
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.̂  °AV = J%.+ 4 (41) 
= ± 0.014 volt , 
where 
u = standard deviation in AV 
o~ = standard deviation in V2 
a— = standard deviation in average voltage V = (Vx -f V3)/2. 
Equation 25 is now used to determine the total dose normalized to 
a monitor reading of 1 X 10° counts. The dose at some point x,y and the 
dose at the reference point (0,2 or o,y) are then used in equation 34 or 
equation 36 to calculate P or F. Expressing the percent dose in terms 
y 
of the measured quantities gives equation 42. 
t = ^ a / [ ( V , + V , ) / 2 - V 2 ] a V d X 10
5 /LC) f l - , , ? , 
C \l(V1 + V 3 ) / 2 - V2 j b A ( l X 10- /LC) b y ' ^ " 
where 
P = percent depth dose (central axis depth dose or traverse 
dose percentage) 
a = the chamber used to determine: the dose at. point x,y 
b = the chamber used to measure the dose at the reference point 
(0,2 cm for the centra] axis depth dose and o,y for the tra-
verse dose percentage) 
LC = long counter reading for given exposure 
C , = calibration factor for chamber a or b (R/volt). 
a, b 
Temperature and pressure corrections are not included in equation 
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42 since there were insignificant changes in these parameters during the 
time required for the two irradiations. 
The standard deviation in the percent dose is controlled by the 
standard deviation of each factor shown in equation 42. The calibration 
factors (C) have boon determined with a percent standard deviation of 
-- 3.0 .H-rcent; for a fixed gamma ray dose. The percent standard deviation 
in the second term, the voltage change caused by the exposure, is given b1 
equation 43. 
/'Percent Standard^. _ AV 
VDeviation in AV / AV 
X 100 (43) 
where 
o = standard deviation in voltage drop AV (0.014 volt) 
AV = voltage drop caused by the exposure (volt). 
A total dose of about 0.75 rad was used for all measurements within 
the neutron beam. Therefore, AV will be of the order of 1.36 volts and 
will have associated with it a standard deviation of ± 1.0 percent. An 
estimated standard deviation of it 0.5 percent was obtained for the long 
counter as explained in Chapter IV. All of these factors are combined as 
shown in equation 44 to obtain the standard deviation in the percent dose. 
/Percent Standard 
VDeviation in P 
r/Percent Percent Percent 
Std. Dev. + .Std. Dev. + 
\l L inC lin AV 
Std. Dev. j(44) 
\ in LC / I 
Introducing the percent standard deviations mentioned above into 
equation 44 leads to a standard deviation of ±4.5 percent in the percent 
dose. 
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It should be noted that systematic errors in the calibration of the 
ionization chambers will not contribute to the error in relative dose 
values such as P . 
Error in Neutron and Gamma Dose 
Gamma dose determination by means of the paired chamber system is 
based on a simultaneous solution of equations 18 and 19. Solving this 
set of equations for the. gamma dose, one obtains equation 45. 
k T - 0.97 G ,, c, 
Y = I T 0 3 — ( 4 3 ) 
As can be seen from this equation, the gamma dose component depends 
directly on the difference between two numbers (k)(T) and 0.97 G. For 
radiation fields with low gamma contamination, the two numbers are of 
about the same size. Therefore, several significant figures may be lost 
in solving for the gamma dose. High percent error may result in the 
gamma dose due to this reduction of significant figures. 
On the other hand, this loss of significant figures is less severe 
for the determination of the neutron dosr. Solving the system of equation: 
for the neutron dose gives the equation shown below. 
N = T " G 
0.97 - k 
The value of T is considerably larger than G for the case of low 
gamma contamination and k is of the order of four times smaller than the 
rad to R conversion factor (0.97). Therefore, the neutron dose has small 
percent error compared to the percent error in the gamma dose. 
Experimental error arises primarily from variations in the current 
obtained from the paired ionization chambers. Values of the percent ex-
perimental error due to current variations are shown in Table 13. The 
major source of error for both the gamma and the neutron dose is the large 
noiso m sienal ratio of the graphite chamber. 
Table 13. Experimental Error in Neutron and Gamma Dose 
Due to Current Variations 
Source Experimental Error Experimental Error 
in Gamma Dose in Neutron Dose 
(%) 0) 
^ ( d . n ^ H e ± 3 ± 1 
?52 
Cf ± 2 4 ± 3 
^ ( d . n ^ H e ± 3 0 ± 2 
PuBe ± 3 4 ± 3 
The variation in the percent error of the gamma dose shown in 
Table 13 is due primarily to the dose rate obtained from each neutron 
source used. 
Due to uncertainty in the neutron response of the graphite cham-
ber, absolute calibration of each chamber for gamma rays and the ratio of 
W values for electrons and protons large systematic errors may result in 
the gamma dose component. 
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Consideration of the uncertainty due to these sources of systematic 
error could result in gamma doses that are a factor of two larger than the 
values given in this study. As a result of this possibility of large sys-
tematic error in gamma dose measurements, the relative gamma dose compo-
Y 




TRAVERSE DOSE FLTNCTIONS AND GAMMA DOSE COMPONENTS 
Values of the traverse dose function (F) are given in Tables 14, 
15, 16, and 17 for each neutron beam investigated in this work. Values 
y 
oi the oercent gamma dose component P are also shown in Tables 14, 15, 
x, y 
16, and 17 and are identified by being enclosed by parentheses. 
Tab le 14. T r a v e r s e l- 'unctions and Gamma Dose Components for 7.5 
14 MeV N e u t r o n s , and SSD of 125 cm 
em Field 
Depth K Disp .acemen t Erom Central Axi 
. s (cm) 
(cm) 
y 10 






2 0.15 0.14 0.20 0.4 3 0.96 1.00 0.981 0.44 0.20 0.13 0.15 
(27) (14) (10) (8) (8) (12) (30) 
4 0.15 0.14 0.21 0.48 0.98 1.00 1.02 0.47 0.20 0.14 0.15 
6 0.16 0.14 0.22 0.521 1.01 1.00 0.980 0.50 0.22 0.15 0.15 
(28) (11) (6) (8) (7) (10) (30) 
8 0.16 0.21 0.26 0.516 0.963 1.00 0.936 0.525 0.27 0.21 0.15 
10 0.19 0.26 0.30 0.546 0.954 1.00 0.945 0.565 0.31 0.26 0.20 
(31) (11) (10) (9) (9) (9) (28) 
12 0.21 0.25 0.32 0.578 0.982 1.00 0.952 0.570 0.32 0.26 0.22 
14 0.20 0.28 0.34 0.552 0.934 1.00 0.921 0.548 0.33 0.28 0.21 
(34) (13) (9) (10) (10) (ID (37) 
16 0.20 0.27 0.34 0.558 0.982 1.00 0.946 0.560 0.33 0.26 0.19 
18 0.24 0.31 0.35 0.574 1.02 1.00 0.920 0.593 0.34 0.32 0.24 
(40) (17) (9) (12) (12) (14) (45) 
20 0.23 0.30 0.39 0.607 0.956 1.00 0.931 0.615 0.38 0.30 0.24 
NOTE ( ) = percent gamma dose component P Y 
ro 
• 
Table 15. Traverse Functions and Gamma Dose Components for 11.4 X 11.4 cm Field, 
14 MeV Neutrons, and SSD of 125 cm 
x Displacement from Central Axis (cm) 
(cm) 
y 12 10 8 6 4 2 0 2 3 4 6 8 10 12 




0 .920 0 . 5 7 1 
(9) 
0 .20 0 .15 
(28) 
0 .11 
4 0 .12 0 .14 0 .21 0 .574 0 .862 0 .970 1.00 0 .980 0 . 8 7 1 0 .570 0 .20 0 .15 0 .11 
6 0 .14 0 .18 0 .25 0 .570 0 .864 0 .982 1.00 
(7) 
0 . 9 9 1 
(8) 
0 .885 0 .570 
(8) 
0 .25 0 .19 
(31) 
0 .14 
8 0 .15 0 .22 0 .28 0 .584 0 .885 b . 967 1.00 1.03 0 .880 0 .575 0 .29 0 .22 0 .15 




0 . 8 9 9 0 .595 
(10) 
0 . 3 4 0 .25 
(34) 
0.16 
12 0 . 2 3 0 .29 0 .34 0 .607 0 .898 0 .988 1.00 0 .992 0 .900 0 .595 0 .35 0 .29 0 .24 




0 .837 0 .660 
( I D 
0 .44 0 .34 
(40) 
0 .27 
16 0 .29 0 .36 0 .44 0 .660 0 .842 0 .984 1.00 0 .973 0.841 0 .660 0 .45 0 .36 0 .28 




0 .810 0 .685 
(10) 
0 .48 0 .38 
(49) 
0 . 3 1 
20 0 . 3 1 0 .39 0 .523 0 .742 0 .854 1.03 1.00 0 .965 0 .842 0 .730 0 . 5 0 0 .40 0 .32 
NOTE: ( ) = percent gamma dose component P Y 
*,y 
Table 16. Traverse Functions and Gamma Dose Components for 13 X 13 cm Field, 14 MeV 
Neutrons, and SSD of 125 cm 
Depth x Dis placement f rom Central Axis (cm) 
(cm) 
y 14 12 10 
g 6 4 3 2 0 2 3 4 6 8 10 12 14 















4 0.09 0.13 0.20 0.26 0.603. 0.943 0.967 1.00 0.983 0.930 0.617 0.26 0.19 0.13 0.10 















8 0.14 0.15 0.22 0.30 0.741 0.942 1.03 1.00 0.982 0.937 0.735 0.31 0.22 0.16 0.13 















12 0.16 0.24 0.30 0.43 0.792 1.00 0.992 1.00 0.953 0.972 0.791 0.42 0.30 0.24 0.17 















16 0.21 0.27 0.32 0.51 0.830 0.992 1.02 1.00 0.977 0.980 0.822 0.50 0.33 0.27 0.21 















20 0.25 0.34 0.40 0.536 0.862 0.962 1.03 1.00 1.02 0.947 0.850 0.55 0.40 0.33 0.25 
NOTE: ( ) = percent gamma dose component P "Y 
Table 17. T r a v e r s e F u n c t i o n s and Gamma Dose Components for 18 .4 X 18 .4 cm F i e l d , 




x D i sp lacemen t f rom C e n t r a l Axis (cm) 
14 12 10 8 6 4 2 0 2 3 4 6 8 10 12 14 




0 .967 0 .940 
( I D 
0 .725 0 . 3 8 0 .26 
(32) 
0 .16 
4 0 .15 0 .27 0 .43 0 .745 0 .983 0.947 0 .972 1.00 0 . 9 8 1 0 .953 0 .962 0 .736 0 . 4 3 0 .26 0 .17 




0 .978 0 .930 
(12) 
0 .752 0 . 4 4 0 . 3 1 
(34) 
0 .20 
8 0 .18 0 .28 0 .506 0 .773 0 .912 0.982 0 .965 1.00 0 .969 0 .971 0 .904 0 .762 0 . 5 0 3 0 . 3 1 0 . 2 1 
10 0 .24 0 .34 0 .512 0 .790 0 .924 0 .943 0 .987 1.00 
(13) 
0 . 9 8 3 
(16) 
0 .967 0 .917 
(14) 
0 .786 0 .565 0 .36 
(35) 
0 .25 
12 0 . 3 1 0 .39 0 .571 0 .834 0 .953 0.976 1.00 1.00 1.01 0 .985 0 .942 0 .846 0 .568 0 .40 0 .29 




0 .973 0 .901 
(16) 
0 . 764 0 .620 0 . 4 3 
(38) 
0 .32 
16 0 .34 0 .44 0 .657 0 .803 0 .945 0 .974 0 .934 1.00 1.02 0 .942 0 .920 0 . 7 8 8 0 .642 0 . 4 3 0 .33 




0 .967 0 .900 
(16) 
0 . 8 1 1 0 .682 0 .46 
(43) 
0 .35 
20 0 .35 0 .47 0 .693 0 .841 0 .957 1.01 0 .984 1.00 1.03 0 .934 0 .912 0 .820 0 . 6 8 1 0 .45 0 .35 
NOTE: ( ) = p e r c e n t gamma dose component P Y 
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APPENDIX C 
FITTING CONSTANTS FOR TRAVERSE EQUATION 
Values of u and c for use in equation 38 are given in Table ll 
for each field size investigated in this study. 
Table 18. Fitting Constants for Traverse Equation (14 MeV Neutrons, SSD = 125 cm) 
Depth F i e l d S i z e \ 7.5 X 7.5 cm 11 .4 X 1 1 . 4 cm 13 X 13 cm 1 8 . 4 X 18 .4 cm 
(cm) £/L R a n g e \ 0 -1 0-2 0-1 0-2 0-1 0-2 0-1 0-2 
y 













































































































































0 . 2 3 
0 . 2 4 
0 .26 
0 .25 
0 . 3 1 
0 . 3 0 
0 .39 
0 .40 
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